Document:

Exhibit 4.1

 

LION
BIOTECHNOLOGIES, Inc.

 

____________________

 

INDENTURE

 

Dated as of [●]

 

[●]

 

Trustee

 

____________________

 

     

     

    

 

TABLE OF CONTENTS

 

	 		Page
	 		 
	ARTICLE 1
	 		 
	DEFINITIONS
	 		 
	SECTION 1.01.	Certain Terms Defined	1
	SECTION 1.02.	Other Definitions	5
	SECTION 1.03.	Rules of Construction	5
	 		 
	ARTICLE 2
	 		 
	SECURITY FORMS
	 		 
	SECTION 2.01.	Forms Generally	5
	SECTION 2.02.	Guarantees by Guarantor; Form of Guarantee; Release of Guarantee	5
	SECTION 2.03.	Form of Trustee’s Certificate of Authentication	7
	 		 
	ARTICLE 3
	 		 
	ISSUE, EXECUTION, FORM AND REGISTRATION OF SECURITIES
	 		 
	SECTION 3.01.	Amount Unlimited; Issuable in Series	8
	SECTION 3.02.	Authentication and Delivery of Securities	10
	SECTION 3.03.	Execution of Securities	10
	SECTION 3.04.	Certificate of Authentication	10
	SECTION 3.05.	Denomination, Currency and Date of Securities; Payments of Interest	10
	SECTION 3.06.	Global Security Legend	11
	SECTION 3.07.	Registration, Transfer and Exchange	12
	SECTION 3.08.	Book-Entry Provisions for Global Securities	13
	SECTION 3.09.	Mutilated, Defaced, Destroyed, Lost and Stolen Securities	14
	SECTION 3.10.	Cancellation of Securities	14
	SECTION 3.11.	Temporary Securities	15
	SECTION 3.12.	CUSIP and ISIN Numbers	15
	 		 
	ARTICLE 4
	 		 
	CERTAIN COVENANTS
	 		 
	SECTION 4.01.	Payment of Principal, Premium and Interest on Securities	15
	SECTION 4.02.	Maintenance of Office or Agency	15
	SECTION 4.03.	Money for Securities Payments to be Held in Trust	16
	SECTION 4.04.	Existence	16
	SECTION 4.05.	Statement by Officers as to Default	16
	SECTION 4.06.	Waiver of Certain Covenants	17
	 		 
	ARTICLE 5
	 		 
	REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT
	 		 
	SECTION 5.01.	Events of Default	17
	SECTION 5.02.	Acceleration	18
	SECTION 5.03.	Other Remedies	18

 

    -i- 

     

    

 

TABLE OF CONTENTS

(continued)

 

	 		Page
	 		 
	SECTION 5.04.	Waiver of Past Defaults	19
	SECTION 5.05.	Control by Majority	19
	SECTION 5.06.	Limitation on Suits	19
	SECTION 5.07.	Rights of Holders to Receive Payment	19
	SECTION 5.08.	Collection Suit by Trustee	20
	SECTION 5.09.	Trustee May File Proofs of Claim	20
	SECTION 5.10.	Priorities	20
	SECTION 5.11.	Undertaking for Costs	20
	SECTION 5.12.	Restoration of Rights and Remedies	21
	SECTION 5.13.	Rights and Remedies Cumulative	21
	SECTION 5.14.	Delay or Omission Not Waiver	21
	 		 
	ARTICLE 6
	 		 
	THE TRUSTEE
	 		 
	SECTION 6.01.	Duties and Responsibilities of the Trustee; During Default; Prior to Default	21
	SECTION 6.02.	Certain Rights of the Trustee	22
	SECTION 6.03.	Trustee Not Responsible for Recitals, Disposition of Securities or Application of Proceeds
    Thereof	23
	SECTION 6.04.	Trustee and Agents May Hold Securities; Collections, Etc	23
	SECTION 6.05.	Moneys Held by Trustee	23
	SECTION 6.06.	Notice of Default	23
	SECTION 6.07.	Compensation and Indemnification of Trustee and Its Prior Claim	24
	SECTION 6.08.	Right of Trustee to Rely on Officers’ Certificate, Etc	24
	SECTION 6.09.	Persons Eligible for Appointment as Trustee	24
	SECTION 6.10.	Resignation and Removal; Appointment of Successor Trustee	25
	SECTION 6.11.	Acceptance of Appointment by Successor	26
	SECTION 6.12.	Merger, Conversion, Consolidation or Succession to Business of Trustee	26
	SECTION 6.13.	Preferential Collection of Claims	27
	SECTION 6.14.	Communications with the Trustee	27
	SECTION 6.15.	Paying Agent/Registrar	27
	 		 
	ARTICLE 7
	 		 
	CONCERNING THE HOLDERS
	 		 
	SECTION 7.01.	Evidence of Action Taken by Holders	27
	SECTION 7.02.	Proof of Execution of Instruments and of Holding of Securities; Record Date	28
	SECTION 7.03.	Who May Be Deemed Owners of Securities	28
	SECTION 7.04.	Securities Owned by Company Deemed Not Outstanding	28
	SECTION 7.05.	Record Date for Action by Holders	28
	SECTION 7.06.	Right of Revocation of Action Taken	28
	 		 
	ARTICLE 8
	 		 
	MEETINGS OF HOLDERS
	 		 
	SECTION 8.01.	Purposes for Which Meeting May Be Called	29
	SECTION 8.02.	Manner of Calling Meetings; Record Date	29
	SECTION 8.03.	Call of Meeting by Company or Holders	29

 

    -ii- 

     

    

 

TABLE OF CONTENTS

(continued)

 

	 		Page
	 		 
	SECTION 8.04.	Who May Attend and Vote at Meeting	30
	SECTION 8.05.	Regulations	30
	SECTION 8.06.	Manner of Voting at Meetings and Record to be Kept	30
	SECTION 8.07.	Exercise of Rights of Trustee and Holders Not to be Hindered or Delayed	31
	 		 
	ARTICLE 9
	 		 
	SUPPLEMENTAL INDENTURES
	 		 
	SECTION 9.01.	Supplemental Indentures Without Consent of Holders	31
	SECTION 9.02.	With Consent of Holders	32
	SECTION 9.03.	Effect of Supplemental Indenture	33
	SECTION 9.04.	Documents to Be Given to Trustee; Compliance with TIA	33
	SECTION 9.05.	Notation on Securities in Respect of Supplemental Indentures	33
	 		 
	ARTICLE 10
	 		 
	CONSOLIDATION, MERGER OR SALE OF ASSETS
	 		 
	SECTION 10.01.	When the Company May Merge, Etc	33
	SECTION 10.02.	Successor Person Substituted	34
	SECTION 10.03.	Opinion of Counsel to Trustee	34
	 		 
	ARTICLE 11
	 		 
	REDEMPTION OF SECURITIES
	 		 
	SECTION 11.01.	Applicability of Article	34
	SECTION 11.02.	Notice of Redemption; Partial Redemptions	34
	SECTION 11.03.	Payment of Securities Called for Redemption	35
	 		 
	ARTICLE 12
	 		 
	DEFEASANCE AND COVENANT DEFEASANCE
	 		 
	SECTION 12.01.	Applicability of the Article; Company’s Option to Effect Defeasance or Covenant Defeasance	35
	SECTION 12.02.	Legal Defeasance and Discharge	36
	SECTION 12.03.	Covenant Defeasance	36
	SECTION 12.04.	Conditions to Legal or Covenant Defeasance	36
	SECTION 12.05.	Deposited Money and Government Securities to be Held in Trust; Other Miscellaneous Provisions	37
	SECTION 12.06.	Repayment to the Company or Guarantor	38
	SECTION 12.07.	Reinstatement	38
	 		 
	ARTICLE 13
	 		 
	SATISFACTION AND DISCHARGE
	 		 
	SECTION 13.01.	Satisfaction and Discharge of Indenture	38
	SECTION 13.02.	Application of Trust Money	39

 

    -iii- 

     

    

 

TABLE OF CONTENTS

(continued)

 

	 		Page
	 		 
	ARTICLE 14
	 		 
	HOLDERS’ LISTS AND REPORTS BY TRUSTEE, COMPANY AND GUARANTORS
	 		 
	SECTION 14.01.	Company to Furnish Trustee Names and Addresses of Holders	39
	SECTION 14.02.	Preservation of Information; Communications to Holders	39
	SECTION 14.03.	Reports by the Trustee	40
	SECTION 14.04.	Reports by the Company and Guarantors	40
	 		 
	ARTICLE 15
	 		 
	MISCELLANEOUS PROVISIONS
	 		 
	SECTION 15.01.	Incorporators, Stockholders, Members, Partners, Officers, Managers and Directors of Company
    or any Guarantor Exempt from Individual Liability	41
	SECTION 15.02.	Provisions of Indenture for the Sole Benefit of Parties and Holders	41
	SECTION 15.03.	Successors and Assigns of Company or Guarantor Bound by Indenture	41
	SECTION 15.04.	Notices, Etc., to Trustee, the Company and Guarantors	41
	SECTION 15.05.	Notices to Holders	41
	SECTION 15.06.	Officers’ Certificates and Opinions of Counsel; Statements to Be Contained Therein	42
	SECTION 15.07.	Payments Due on Saturdays, Sundays and Holidays	42
	SECTION 15.08.	Conflict of Any Provision of Indenture with Trust Indenture Act	43
	SECTION 15.09.	Conflict of Any Provision of Securities with Indenture	43
	SECTION 15.10.	New York Law to Govern	43
	SECTION 15.11.	Waiver of Jury Trial	43
	SECTION 15.12.	Consent to Jurisdiction and Service	43
	SECTION 15.13.	Third Party Beneficiaries	43
	SECTION 15.14.	Counterparts	43
	SECTION 15.15.	Effect of Headings, Table of Contents	43
	SECTION 15.16.	No Adverse Interpretation of Other Agreements	43
	SECTION 15.17.	Severability	43
	SECTION 15.18.	Patriot Act Compliance	44
	SECTION 15.19.	Force Majeure	44

 

    -iv- 

     

    

 

LION
BIOTECHNOLOGIES, INC. 

Reconciliation and tie between Trust Indenture Act of 1939, as amended,

and this Indenture

	Trust Indenture Act

           Section	 	Indenture

Section
	§310	(a)(1)	 	6.09
	 	(a)(2)	 	6.09
	 	(a)(3)	 	Not Applicable
	 	(a)(4)	 	Not Applicable
	 	(a)(5)	 	6.09
	 	(b)	 	6.04, 6.10
	§311	(a)	 	6.13
	 	(b)	 	6.13
	§312	(a)	 	14.01, 14.02(a)
	 	(b)	 	14.02(b)
	 	(c)	 	14.02(c)
	§313	(a)	 	14.03(a)
	 	(b)	 	14.03(a)
	 	(c)	 	14.03(a), 14.03(b)
	 	(d)	 	14.03(b)
	§314	(a)	 	4.05, 14.04
	 	(b)	 	Not Applicable
	 	(c)(1)	 	15.06
	 	(c)(2)	 	15.06
	 	(c)(3)	 	Not Applicable
	 	(d)	 	Not Applicable
	 	(e)	 	15.06
	§315	(a)	 	6.01
	 	(b)	 	6.06, 14.03(a)
	 	(c)	 	6.01
	 	(d)	 	6.01
	 	(e)	 	5.11
	§316	(a)(1)(A)	 	5.05
	 	(a)(1)(B)	 	5.02, 5.04
	 	(a)(2)	 	Not Applicable
	 	(b)	 	5.07
	 	(c)	 	7.02, 8.03
	§317	(a)(1)	 	5.08
	 	(a)(2)	 	5.09
	 	(b)	 	4.03
	318	(a)	 	15.08

 

This cross-reference table shall not, for any purpose, be deemed
to be part of this Indenture.

 

     

     

    

 

INDENTURE dated as of [●] between
Lion Biotechnologies, Inc., a Nevada corporation (the “Company”), the Guarantors (as defined herein) and [●],
as trustee (the “Trustee”).

 

WITNESSETH:

 

WHEREAS, the Company and the Guarantors
have duly authorized the execution and delivery of this Indenture to provide for the issuance from time to time of its unsecured
debentures, notes or other evidences of indebtedness (herein called the “Securities”), to be issued in one or more
series as in this Indenture provided; and

 

WHEREAS, all things necessary to make the
Indenture a valid indenture and agreement according to its terms, have been done.

 

NOW, THEREFORE:

 

In consideration of the premises and the
purchases of the Securities by the Holders thereof, the Company, the Guarantors and the Trustee mutually covenant and agree for
the equal and proportionate benefit of the respective Holders from time to time of the Securities as follows:

 

ARTICLE 1

DEFINITIONS

 

SECTION 1.01.         Certain
Terms Defined. The following terms (except as otherwise expressly provided or unless the context otherwise clearly requires)
for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this
Section. All other terms used in this Indenture which are defined in the Trust Indenture Act or the definitions of which in the
Securities Act are referred to in the Trust Indenture Act (except as herein otherwise expressly provided or unless the context
otherwise clearly requires), shall have the meanings assigned to such terms in the Trust Indenture Act and in the Securities Act
as in force at the date of this Indenture. All accounting terms used herein and not expressly defined shall have the meanings
given to them in accordance with generally accepted accounting principles in the United States (whether or not such is indicated
herein). The words “herein,” “hereof” and “hereunder” and other words of similar import refer
to this Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in this Article
include the plural as well as the singular.

 

“Agent Members” has the meaning
provided in Section 3.08(a).

 

“Board of Directors” means,
with respect to any Person, the board of directors or board of managers of such Person, or any authorized committee of the board
of directors or board of managers of such Person or any officer of such Person duly authorized by the board of directors or board
of managers of such Person to take a specific action.

 

“Board Resolution” means, with
respect to the Company or any Guarantor, a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company
or such Guarantor, respectively, to have been duly adopted by the Board of Directors of the Company or such Guarantor, respectively,
and to be in full force and effect on the date of such certification, and delivered to the Trustee.

 

“Business Day” means any day
except a Saturday, Sunday or other day on which banking institutions or trust companies located in the same jurisdiction as the
Payment Office specified pursuant to Section 3.01 are authorized or obligated by law or executive order to close, except as otherwise
specified pursuant to Section 3.01.

 

“Commission” means the United
States Securities and Exchange Commission, as from time to time constituted, created under the Exchange Act, or, if at any time
after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust
Indenture Act, then the body performing such duties at such time.

 

     

     

    

 

“Company” means the Person named
as the “Company” in the first paragraph of this Indenture until a successor shall have become such pursuant to the
applicable provisions of this Indenture, and thereafter “Company” shall mean such successor.

 

“Company Request” or “Company
Order” means a written request or order signed in the name of the Company by its Chairman of the Board of Directors, its
President, its Chief Executive Officer, its Chief Financial Officer, its Treasurer, its Controller, its Secretary or an Assistant
Secretary, and delivered to the Trustee.

 

“Corporate Trust Office” means
the corporate trust office of the Trustee at which the corporate trust business of the Trustee shall, at any particular time, be
principally administered, which office is, at the date as of which this Indenture is dated, located at [●].

 

“Default” means any event that
is or with the passage of time or the giving of notice or both would be an Event of Default.

 

“Depositary” means The Depository
Trust Company, its nominees, and their respective successors.

 

“Dollar” or “$”
means a dollar or other equivalent unit in such coin or currency of the United States as at the time shall be legal tender for
the payment of public and private debt.

 

“Event of Default” means any
event or condition specified as such in Section 5.01 which shall have continued for the period of time, if any, therein designated.

 

“Exchange Act” means the Securities
Exchange Act of 1934, as amended.

 

“GAAP” means generally accepted
accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board of the
American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board
or in such other statements by such other entity as may be approved by a significant segment of the accounting profession of the
United States, as in effect from time to time. At any time after the Issue Date with respect to a series of Securities, the Company
may elect to apply IFRS in lieu of GAAP and, upon any such election, references in this Indenture to GAAP shall thereafter be construed
to mean IFRS as in effect from time to time. The Company shall give notice of any such election to the Trustee.

 

“Global Security” means a Security,
and any Guarantees endorsed thereon, evidencing all or part of a series of Securities and the corresponding Guarantees, if any,
issued to the Depositary for that series in accordance with Section 3.05 and bearing the appropriate legend prescribed in Section
3.06.

 

“Government Securities” means
direct obligations of, or obligations guaranteed by, the United States of America, and the payment for which the United States
pledges its full faith and credit.

 

“Guarantee” means with respect
to the Securities of any series, the Guarantee with respect to the Securities of such series by the applicable Guarantor or Guarantors
pursuant to Section 2.02 hereof and a supplemental indenture.

 

“Guarantor”
means, with respect to Securities of any series, any of the Company’s direct and indirect Subsidiaries, but only
if such entity has guaranteed the Company’s obligations under this Indenture and with respect to such series of
Securities pursuant to Section 2.01 hereof; provided that upon the release and discharge of any Person from its
Guarantee in accordance with this Indenture or as specified pursuant to Section 3.01, such Person shall cease to be a
Guarantor.

 

“Holder,” “Holder of Securities”
or other similar terms mean the registered holder of any Security.

 

    	 	-2-	 

     

    

 

“IFRS” means International Financial
Reporting Standards promulgated by the International Accounting Standards Board (or any successor board or agency) and as adopted
by the European Union, as in effect from time to time.

 

“Indenture” means this indenture
as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto
entered into pursuant to the applicable provisions hereof and shall include the terms of particular series of Securities established
as contemplated hereunder.

 

“Interest Payment Date” means,
when used with respect to any Security, the Stated Maturity of an installment of interest on such Security.

 

“Issue Date” means, with respect
to Securities of a series, the first date on which the Securities of such series are originally issued under this Indenture.

 

“Maturity,” means, when used
with respect to any Security, the date on which the principal of such Security or an installment of principal becomes due and payable
as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.

 

“Notice of Default” has the
meaning provided in Section 6.06.

 

“Officers’ Certificate”
means a certificate signed on behalf of the Company by an officer of the Company (or on behalf of a Guarantor by an officer of
such Guarantor, as the case may be) that meets the requirements of Section 15.06 hereof.

 

“Opinion of Counsel” means an
opinion in writing signed by legal counsel who may be an employee of or counsel to the Company or a Guarantor or who may be other
counsel satisfactory to the Trustee.

 

“outstanding” means, when used
with reference to Securities, subject to the provisions of Article 7, as of any particular time, all Securities authenticated
and delivered by the Trustee under this Indenture, except

 

(a)          Securities theretofore
canceled by the Trustee or delivered to the Trustee for cancellation;

 

(b)          Securities,
or portions thereof, for the payment or redemption of which moneys in the necessary amount shall have been deposited in trust
with the Trustee or with any Paying Agent (other than the Company or a Guarantor) or shall have been set aside, segregated
and held in trust by the Company or a Guarantor (if the Company or a Guarantor shall act as Paying Agent); provided
that if such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given
as herein provided, or provision satisfactory to a Responsible Officer of the Trustee shall have been made for giving
such notice;

 

(c)          Securities in substitution
for which other Securities shall have been authenticated and delivered, or which shall have been paid, pursuant to the terms of
Section 3.09 (unless proof satisfactory to the Trustee and the Company is presented that any of such Securities is held by
a person in whose hands such Security is a legal, valid and binding obligation of the Company); and

 

(d)          Securities that have
been defeased pursuant to Section 12.01.

 

“Paying Agent” means any Person
authorized by the Company to pay the principal of (and premium, if any) and interest, if any, on any Securities on behalf of the
Company. The Company or a Guarantor may act as Paying Agent with respect to any Securities issued hereunder.

 

“Payment Office” means, when
used with respect to the Securities of or within any series, the place or places where the principal of (and premium, if any) and
interest on such Securities are payable as specified pursuant to Section 3.01.

 

    	 	-3-	 

     

    

 

“Person” means any individual,
corporation, partnership, joint stock company, business trust, trust, unincorporated association, joint venture or other entity
or organization, including a government or political subdivision or an agency or instrumentality thereof.

 

“Physical Securities” means
Securities issued pursuant to Section 3.02 in exchange for interest in the Global Security or pursuant to Section 3.08(b)
in registered form substantially in the form hereinabove recited.

 

“Principal Amount” means, when
used with respect to any Security, the amount of principal of such Security that could then be declared due and payable pursuant
to Section 5.02.

 

“Registrar” has the meaning
provided in Section 3.07.

 

“Regular Record Date” for the
interest payable on any Interest Payment Date on the Securities of any series means the date specified for that purpose as contemplated
by Section 3.01.

 

“Responsible Officer” means,
when used with respect to the Trustee, any officer within the Corporate Trust Office of the Trustee including any vice president,
any trust officer, any assistant vice president, any assistant secretary, any assistant treasurer, or any other officer of the
Trustee customarily performing functions similar to those performed by the persons who at the time shall be such officers, respectively,
or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject
and who shall have direct responsibility for the administration of this Indenture.

 

“Securities Act” means the Securities
Act of 1933, as amended.

 

“Security” or “Securities”
means any Security or Securities, as the case may be, authenticated and delivered under this Indenture.

 

“Security Register” has the
meaning provided in Section 3.07.

 

“Stated Maturity” means, when
used with respect to any Security or any installment of principal thereof or interest thereon, the date specified in such Security
or a coupon representing such installment of interest as the fixed date on which the principal of such Security or such installment
of principal or interest is due and payable.

 

“Subsidiary” means, as applied,
with respect to any Person, any corporation, partnership or other legal entity of which, in the case of a corporation, more than
50% of the issued and outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such
corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation has or might have
voting power upon the occurrence of any contingency), or, in the case of any partnership or other legal entity, more than 50% of
the ordinary equity capital interests, is at the time directly or indirectly owned or controlled by such Person, by such Person
and one or more of its other Subsidiaries or by one or more of such Person’s other Subsidiaries.

 

“Trust Indenture Act” means
the Trust Indenture Act of 1939, as amended, as in force at the date as of which this Indenture was originally executed, and “TIA”
means, when used in respect of an indenture supplemental hereto, such Act as in force at the time such indenture supplemental hereto
becomes effective.

 

“Trustee” means the Person named
as the “Trustee” in the first paragraph of this Indenture until a successor Trustee shall have become such pursuant
to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each Person who is then
a Trustee hereunder; provided that if at any time there is more than one such Person, “Trustee” as used with
respect to the Securities of any series shall mean only the Trustee with respect to Securities of that series.

 

    	 	-4-	 

     

    

 

SECTION 1.02.         Other
Definitions.

 

	Term	 	Defined in Section
	“Authorized Agent”	 	15.12
	“Covenant Defeasance”	 	12.03
	“Legal Defeasance”	 	12.02
	“Specified Courts”	 	15.12

 

SECTION 1.03.         Rules
of Construction.

 

Unless the context otherwise requires:

 

(a)          a
term has the meaning assigned to it;

 

(b)          an
accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;

 

(c)          “or”
is not exclusive;

 

(d)          words
in the singular include the plural, and in the plural include the singular;

 

(e)          provisions
apply to successive events and transactions; and

 

(f)          all
references in this instrument to Articles and Sections are references to the corresponding Articles and Sections in and of this
instrument unless the context requires otherwise.

 

ARTICLE 2

SECURITY FORMS

 

SECTION 2.01.         Forms
Generally. The Securities of each series, and all Guarantees endorsed thereon, if any, shall be in substantially the forms
as shall be established by or pursuant to a Board Resolution of the Company (and a Board Resolution of each Guarantor with respect
to the Guarantees, if any) or in one or more indentures supplemental hereto, in each case with such appropriate insertions, omissions,
substitutions and other variations as are required or permitted by this Indenture, and may have such letters, numbers or other
marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities
exchange or as may, consistently herewith, be determined by the officers executing such Securities and Guarantees, if any, as
evidenced by their execution of the Securities and Guarantees. If the form of Securities of any series, and any Guarantees endorsed
thereon, is established by action taken pursuant to a Board Resolution, a copy of an appropriate record of such action shall be
certified by the Secretary or an Assistant Secretary of the Company, and by the Secretary or Assistant Secretary of the Guarantors,
if any, and delivered to the Trustee at or prior to the delivery of the Company Order contemplated by Section 3.02 for the
authentication and delivery of such Securities.

 

The Trustee’s certificate of authentication
on all Securities shall be in substantially the form set forth in this Article.

 

The definitive Securities of any series
shall be printed, lithographed or engraved on steel-engraved borders or may be produced in any other manner, all as determined
by the officers executing such Securities, as evidenced by their execution of such Securities.

 

SECTION 2.02.         Guarantees
by Guarantor; Form of Guarantee; Release of Guarantee.

 

(a)          Except
as otherwise specified in or pursuant to the Officers’ Certificate or supplemental indenture contemplated by Section 3.01(b),
the provisions of this Section 2.02 will be applicable to any series of Securities that is to be guaranteed by one or more Guarantors.

 

    	 	-5-	 

     

    

 

(b)         Each
Guarantor by its execution of this Indenture hereby agrees with each Holder of a Security of each series that is guaranteed by
such Guarantor and authenticated and delivered by the Trustee and with the Trustee on behalf of each such Holder, to be unconditionally
bound by the terms and provisions of the Guarantee set forth below and authorizes the Trustee to confirm such Guarantee to the
Holder of each such Security by its execution and delivery of each such Security, with such Guarantee endorsed thereon, authenticated
and delivered by the Trustee.

 

Guarantees to be endorsed on the Securities
shall, subject to this Section 2.02, be in substantially the form set forth below:

 

GUARANTEE

OF

[GUARANTOR]

 

For value received, [●] (the “Guarantor”)
hereby unconditionally and irrevocably guarantees, jointly and severally, to the Holder of the Security upon which this Guarantee
is endorsed and to the Trustee on behalf of each such Holder the due and punctual payment of the principal of, premium, if any,
interest and additional amounts, if any, on such Security and the due and punctual payment of any sinking fund or analogous payments
referred to therein, if any, when and as the same shall become due and payable, whether on the Stated Maturity, by declaration
of acceleration, call for redemption or otherwise, according to the terms thereof and of the Indenture dated as of [●] among
Lion Biotechnologies, Inc. (hereinafter called the “Company,” which term includes any successor Person thereto under
the Indenture), the Guarantors (as defined therein) and [●], as trustee (the “Indenture” and as supplemented
by any applicable supplemental indenture, the “Indenture”). In case of the failure of the Company punctually to make
any such payment of principal, premium, if any, or interest, and additional amounts, if any, or any sinking fund or analogous payment,
the Guarantor, for so long as this Guarantee shall be in effect, hereby agrees to cause any such payment to be made to or to the
order of the Trustee punctually when and as the same shall become due and payable, whether on the Stated Maturity or by declaration
of acceleration, call for redemption or otherwise, and as if such payment were made by the Company.

 

The Guarantor hereby agrees, to the extent
permitted by law, that its obligations hereunder shall be as if it were the principal debtor and not merely surety, and shall be
absolute and unconditional, irrespective of, and shall be unaffected by, any invalidity, irregularity or unenforceability of such
Security or the Indenture, any failure to enforce the provisions of such Security or the Indenture, or any waiver, modification
or indulgence granted to the Company with respect thereto, by the Holder of such Security or the Trustee or any other circumstance
which may otherwise constitute a legal or equitable discharge of a surety or guarantor. The Guarantor hereby waives, to the extent
permitted by law, diligence, presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy
of the Company, any right to require a proceeding first against the Company, protest or notice with respect to such Security or
the indebtedness evidenced thereby or with respect to any sinking fund or analogous payment required under such Security and all
demands whatsoever, and covenants that this Guarantee will not be discharged except by payment in full of the principal of, premium,
if any, and interest on such Security or as otherwise described in Section 2.02 of the Indenture.

 

This Guarantee shall be automatically and
unconditionally released on the terms set forth in Section 2.02(c) of the Indenture and such terms as have been specified pursuant
to Section 3.01.

 

The Guarantor shall be subrogated to
all rights of the Holder of such Security and the Trustee against the Company in respect of any amounts paid to such Holder
by the Guarantor pursuant to the provisions of this Guarantee; provided that the Guarantor shall not be entitled to
enforce, or to receive any payments arising out of or based upon such right of subrogation until the principal of, premium,
if any, and interest on all Securities of the same series issued under the Indenture shall have been paid in full.

 

The Guarantor hereby agrees that its obligations
hereunder shall be direct, unconditioned and unsubordinated and will rank equally and ratably without preference and at least equally
with other senior unsecured and unsubordinated obligations of the Guarantor, except to the extent prescribed by law. The Holder
of a guaranteed Security will be entitled to payment under the Guarantee without taking any action whatsoever against the Company.

 

    	 	-6-	 

     

    

 

No reference herein to the Indenture and
no provision of this Guarantee or of the Indenture shall alter or impair the guarantee of the Guarantor, which is absolute and
unconditional, of the due and punctual payment of the principal of, premium, if any, and interest on, any additional amounts, and
any sinking fund or analogous payments with respect to, the Security upon which this Guarantee is endorsed.

 

This Guarantee shall not be valid or obligatory
for any purpose until the certificate of authentication of such Security shall have been manually executed by or on behalf of the
Trustee under the Indenture.

 

All terms used in this Guarantee that are
defined in the Indenture shall have the meanings assigned to them in the Indenture.

 

This Guarantee shall be governed by and
construed in accordance with the laws of the State of New York, but without giving effect to applicable principles of conflicts
of law to the extent that the application of the law of another jurisdiction would be required thereby.

 

Executed and dated the date on the face hereof.

 

[GUARANTOR]

 

	By:	 	 
	 	Name:	 
	 	Title:	 

 

(c)          Release
of Guarantee.

 

(i)          The
Guarantee of a Guarantor relating to a series of Securities shall be released automatically and unconditionally, and such Guarantor
shall be relieved of all of its obligations under its Guarantee of such Securities, (A) upon defeasance or discharge of such series
of Securities as provided in Article 12 or Article 13 of this Indenture, (B) if for any reason, such Guarantor ceases to be a Subsidiary
of the Company, or (C) in connection with any sale, disposition or transfer of all or substantially all of the assets of that Guarantor
(including by way of merger or consolidation) to a Person that is not (either before or after giving effect to such transaction)
the Company or a Subsidiary of the Company.

 

(ii)         The
Guarantee of a Guarantor relating to a series of Securities shall be released automatically and unconditionally, and such Guarantor
shall be relieved of all of its obligations under its Guarantee of such Securities, in any additional circumstances provided in
the terms of the Securities of such series established pursuant to Section 3.01 of this Indenture and any relevant supplemental
indenture.

 

(iii)        At
such time as a Guarantor’s Guarantee is released with respect to any series of Securities, such Guarantor will no longer
be considered a “Guarantor” of such series of Securities.

 

(iv)        The
Trustee shall promptly execute any documents reasonably requested by the Company or applicable Guarantor relating to a series
of Securities in order to evidence the release of such Guarantor from its obligations under its Guarantee of the Securities
of such series; provided that the Trustee shall not be obligated to execute or deliver any document evidencing the
release of a Guarantee pursuant to this Section 2.02(c) unless the Company has delivered an Officers’ Certificate or an
Opinion of Counsel to the effect that such release is in accordance with the provisions of this Indenture.

 

SECTION 2.03.         Form
of Trustee’s Certificate of Authentication. The Trustee’s certificate of authentication shall be substantially
in the following form:

 

This is one of the Securities of the series
designated therein referred to in the within-mentioned Indenture.

 

    	 	-7-	 

     

    

 

	 	[____________________________],
	 	as Trustee
	 	 
	 	By:	 
	 	 	Authorized Signatory

 

ARTICLE 3

ISSUE, EXECUTION, FORM AND REGISTRATION OF SECURITIES

 

SECTION 3.01.         Amount
Unlimited; Issuable in Series.

 

(a)          The
aggregate principal amount of Securities which may be authenticated and delivered under this Indenture is unlimited.

 

(b)          The
Securities may be issued from time to time in one or more series. Prior to the issuance of Securities of any series, there shall
be established in or pursuant to (i) a Board Resolution of the Company and each Guarantor, if any, of the Securities of such
series, (ii) action taken pursuant to a Board Resolution and (subject to Sections 3.03 and 3.04) set forth, or determined
in the manner provided, in an Officers’ Certificate of the Company and each Guarantor, if any, of the Securities of such
series, or (iii) one or more indentures supplemental hereto:

 

(1)           the
title of the Securities of the series (which shall distinguish the Securities of the series from all other Securities);

 

(2)           whether
or not such Securities are to be guaranteed pursuant to Section 2.02 and, if so, the Guarantor or Guarantors thereof;

 

(3)           the
purchase price, denomination and any limit upon the aggregate principal amount of the Securities of the series which may be authenticated
and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange
for, or in lieu of, other Securities of the series pursuant to Sections 3.07, 3.09, 3.11, 9.05 or 11.03);

 

(4)           the
date or dates on which the principal of and premium, if any, on the Securities of the series is payable or the method of determination
thereof;

 

(5)           the
rate or rates at which the Securities of the series shall bear interest, if any, or the method of calculating such rate or rates
of interest, the date or dates from which such interest shall accrue or the method by which such date or dates shall be determined,
the Interest Payment Dates on which any such interest shall be payable and the Regular Record Date, if any, for the interest payable
on any Interest Payment Date;

 

(6)           the
place or places where the principal of (and premium, if any) and interest, if any, on Securities of the series shall be payable;

 

(7)           the
place or places where the Securities may be exchanged or transferred;

 

(8)           the
period or periods within which, the price or prices at which, the currency or currencies (including currency unit or units) in
which, and the other terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option
of the Company, if the Company is to have that option, and, if other than as provided in Section 11.02, the manner in which
the particular Securities of such series (if less than all Securities of such series are to be redeemed) are to be selected for
redemption;

 

    	 	-8-	 

     

    

 

(9)           the
obligation, if any, of the Company to redeem or purchase Securities of the series in whole or in part pursuant to any sinking fund
or analogous provisions or upon the happening of a specified event or at the option of a Holder thereof and the period or periods
within which, the price or prices at which, and the other terms and conditions upon which Securities of the series shall be redeemed
or purchased, in whole or in part, pursuant to such obligation;

 

(10)           if
other than denominations of $2,000 and multiples of $1,000 in excess thereof, the denominations in which Securities of the series
shall be issuable;

 

(11)          if
other than Dollars, the currency or currencies (including currency unit or units) in which payments of principal of (and premium,
if any) and interest, if any, on the Securities of the series shall or may by payable, or in which the Securities of the series
shall be denominated, and the particular provisions applicable thereto;

 

(12)         if
the payments of principal of (and premium, if any) and interest, if any, on the Securities of the series are to be made, at the
election of the Company or a Holder, in a currency or currencies (including currency unit or units) other than that in which such
Securities are denominated or designated to be payable, the currency or currencies (including currency unit or units) in which
such payments are to be made, the terms and conditions of such payments and the manner in which the exchange rate with respect
to such payments shall be determined, and the particular provisions applicable thereto;

 

(13)           if
the amount of payments of principal of (and premium, if any) and interest, if any, on the Securities of the series shall be determined
with reference to any commodities, currencies or indices, values, rates or prices or any other index, formula or method (which
index, formula or method may be based, without limitation, on a currency or currencies (including currency unit or units) other
than that in which the Securities of the series are denominated or designated to be payable), the manner in which such amounts
shall be determined;

 

(14)           if
other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable
upon declaration of acceleration of the Maturity thereof pursuant to Section 5.02 or the method by which such portion shall
be determined;

 

(15)           any
modifications of or additions to the Events of Default set forth in Section 5.01 or the covenants of the Company set forth in Article
4 or Article 10 with respect to Securities of the series; and whether such additional or modified Events of Default or covenants
are subject to covenant defeasance pursuant to Section 12.03;

 

(16)           if
either or both of Section 12.02 and Section 12.03 shall be inapplicable to the Securities of the series
(provided that if no such inapplicability shall be specified and the Securities of such series are not convertible
into or their value is not determined with reference to the Company’s equity securities, then both Section 12.02
and Section 12.03 shall be applicable to the Securities of such series; provided further that if no such
inapplicability shall be specified and the Securities of such series are convertible into or their value is determined with
reference to the Company’s equity securities, then neither Section 12.02 nor Section 12.03 shall be
applicable to the Securities of such series) and any other terms upon which the Securities of such series will be
defeasible;

 

(17)           if
other than the Trustee, the identity of the Registrar and any Paying Agent;

 

(18)           if
the Securities of the series shall be issued in whole or in part in global form, (i) the Depositary for such global Securities,
(ii) the form of any legend in addition to or in lieu of that in Section 3.06 which shall be borne by such global Security,
(iii) whether beneficial owners of interests in any Securities of the series in global form may exchange such interests for
certificated Securities of such series and of like tenor of any authorized form and denomination, and (iv) if other than as
provided in Section 3.08, the circumstances under which any such exchange may occur;

 

    	 	-9-	 

     

    

 

(19)           if,
and the terms and conditions upon which, the Securities of such series may or must be converted into securities of the Company
or exchanged for securities of the Company or another enterprise; and

 

(20)           any
other terms of the series or any Guarantees endorsed thereon (which terms shall not adversely affect a prior series of Securities).

 

All Securities of any one series shall be
substantially identical except as to denomination and except as may otherwise be provided (i) by a Board Resolution of the
Company, (ii) by action taken pursuant to a Board Resolution of the Company and (subject to Sections 3.02-3.05) set forth,
or determined in the manner provided, in an Officers’ Certificate or (iii) in any such indenture supplemental hereto.
All Securities of any one series need not be issued at the same time and, unless otherwise provided, a series may be reopened,
without the consent of the Holders, for issuances of additional Securities of such series.

 

If any of the terms of the Securities of
any series, and any Guarantees endorsed thereon, are established by action taken pursuant to a Board Resolution of the Company
and the Guarantors, if any, a copy of an appropriate record of such action shall be certified by the Secretary or an Assistant
Secretary of the Company and the Guarantors, if any, and delivered to the Trustee at or prior to the delivery of the Officers’
Certificate setting forth, or providing the manner for determining, the terms of the Securities of such series, and an appropriate
record of any action taken pursuant thereto in connection with the issuance of any Securities of such series shall be delivered
to the Trustee prior to the authentication and delivery thereof.

 

SECTION 3.02.         Authentication
and Delivery of Securities. Upon the execution and delivery of this Indenture, or from time to time thereafter, Securities
of any series and any Guarantees endorsed thereon may be executed by the Company and the Guarantors, if any, and delivered by
the Company to the Trustee for authentication, together with a Company Order, and upon delivery to the Trustee of all documents
and certificates as required by this Indenture, the Trustee shall thereupon, in accordance with such Company Order, authenticate
and make available for delivery said Securities.

 

SECTION 3.03.         Execution
of Securities. The Securities of each series shall be executed on behalf of the Company, and each of the Guarantees, if any,
shall be executed on behalf of the applicable Guarantor, by the Chairman of the Board of Directors, the President, the Chief Executive
Officer, the Chief Financial Officer, the Treasurer, the Controller, the Secretary or any Assistant Secretary of the Company or
of such Guarantor, as the case may be. The signatures of any of such officers on the Securities or the Guarantees may be the manual
or facsimile signatures of the present or any future such officers. In case any officer of the Company or of each Guarantor, if
any, who shall have signed any of the Securities and Guarantees, if any, shall cease to be such officer before the Security so
signed or to which the Guarantee relates shall be authenticated and delivered by the Trustee or disposed of by the Company, such
Security nevertheless may be authenticated and delivered or disposed of as though the person who signed such Security or Guarantee
had not ceased to be such officer of the Company or of such Guarantor, as the case may be; and any Security or Guarantee may be
signed on behalf of the Company or of a Guarantor, if any, by such persons as shall be the proper officers of the Company or of
such Guarantor, as the case may be, at the actual date of the execution of such Security or Guarantee even though any such person
was not such officer at the date of the execution and delivery of this Indenture.

 

SECTION 3.04.         Certificate
of Authentication. Only such Securities or Guarantees endorsed thereon, if any, as shall bear thereon a certificate of authentication
substantially in the form hereinabove recited, executed by the Trustee by manual signature of one of its authorized signatories,
shall be entitled to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee
upon any Security executed by the Company shall be conclusive evidence that the Security so authenticated has been duly authenticated
and delivered hereunder and that the Holder is entitled to the benefits of this Indenture.

 

SECTION 3.05.         Denomination,
Currency and Date of Securities; Payments of Interest.

 

(a)          The
Securities shall be issuable in such denominations and currency as shall be specified as contemplated by Section 3.01. In the absence
of any specification pursuant to Section 3.01 with respect to Securities of any series, the Securities of such series shall be
denominated in Dollars, issuable only as Securities in denominations of $2,000 and multiples of $1,000 in excess thereof and payable
only in Dollars. The Securities shall be numbered, lettered, or otherwise distinguished in such manner or in accordance with such
plans as the officers of the Company executing the same may determine with the approval of the Trustee.

 

    	 	-10-	 

     

    

 

Any of the Securities and Guarantees, if
any, may be issued with appropriate insertions, omissions, substitutions and variations, and may have imprinted or otherwise reproduced
thereon such legend or legends, not inconsistent with the provisions of this Indenture, as may be required to comply with any law
or with any rules or regulations pursuant thereto, including those required by Section 3.06, or with the rules of any securities
market in which the Securities are admitted to trading, or to conform to general usage.

 

Each Security shall be dated the date of
its authentication, shall bear interest from the applicable date and shall be payable on the dates specified on the face of the
form of Security above. Except as otherwise specified as contemplated by Section 3.01 for Securities of any series, interest on
the Securities of each series shall be computed on the basis of a 360-day year of twelve 30-day months.

 

(b)          Global
Securities. If Securities of or within a series are issuable in whole or in part in global form, then any such Security of
such series shall be deposited with the Trustee as custodian for the Depositary and registered in the name of Cede & Co., as
nominee for the Depositary. The Global Security shall be deposited on behalf of the purchasers of the Securities represented thereby
with the Trustee, as custodian for the Depositary (or with such other custodian as the Depositary may direct), and registered in
the name of the Depositary or a nominee of the Depositary, duly executed by the Company and each Guarantor, if any, and authenticated
by the Trustee as hereinafter provided. The aggregate principal amount of the Global Securities may from time to time be increased
or decreased by adjustments made on the records of the Trustee and the Depositary or its nominee as hereinafter provided.

 

(c)          The
person in whose name any Security is registered at the close of business on any Regular Record Date with respect to any Interest
Payment Date shall be entitled to receive the interest, if any, payable on such Interest Payment Date notwithstanding any transfer
or exchange of such Security subsequent to the Regular Record Date and prior to such Interest Payment Date, except if and to the
extent the Company or a Guarantor, if any, shall default in the payment of the interest due on such Interest Payment Date, in which
case such defaulted interest, plus (to the extent lawful) any interest payable on the defaulted interest, shall be paid to the
persons in whose names outstanding Securities are registered at the close of business on a subsequent record date (which shall
be not less than five Business Days prior to the date of such payment) established by notice given by mail by or on behalf of the
Company or such Guarantor to the Holders of Securities not less than 15 calendar days preceding such subsequent record date.

 

SECTION 3.06.         Global
Security Legend. Any Security in global form authenticated and delivered hereunder shall bear a legend in substantially the
following form, or in such other form as may be necessary or appropriate to reflect the arrangements with or to comply with the
requirements of any Depositary:

 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING
OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH
MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES.

 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT,
AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & Co. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & Co. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY
OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & Co., HAS AN INTEREST HEREIN.

 

    	 	-11-	 

     

    

 

TRANSFERS OF THIS GLOBAL SECURITY SHALL BE LIMITED
TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF THE DEPOSITORY TRUST COMPANY OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S
NOMINEE.

 

SECTION 3.07.         Registration,
Transfer and Exchange. The Securities are issuable only in registered form. The Company will keep at each office or agency
(the “Registrar”) for each series of Securities a register or registers (the “Security Register(s)”) in
which, subject to such reasonable regulations as it may prescribe, it will register, and will register the transfer of Securities
as provided in this Article. Such Security Register or Security Registers shall be in written form in the English language or
in any other form capable of being converted into such form within a reasonable time. At all reasonable times such Security Register
or Security Registers shall be open for inspection by the Trustee. The initial Registrar shall be the Trustee.

 

Upon due presentation for registration of
transfer of any Security of any series at each such office or agency, the Company shall execute a new Security or Securities of
the same series, in each case, of any authorized denominations and of a like aggregate Principal Amount in the name of the designated
transferee or transferees, the applicable Guarantors, if any, shall execute the Guarantees endorsed thereon and, upon receipt of
a Company Order, the Trustee shall authenticate and make available for delivery such Securities.

 

At the option of the Holder, Securities
of any series (except a Security in global form) may be exchanged for other Securities of the same series, of any authorized denominations
and of a like aggregate Principal Amount and Stated Maturity, upon surrender of the Securities to be exchanged at such office or
agency. Whenever any Securities are so surrendered for exchange, the Company shall execute the Securities which the Holder making
the exchange is entitled to receive, the applicable Guarantors, if any, shall execute the Guarantees endorsed thereon and, upon
receipt of a Company Order, the Trustee shall authenticate and make available for delivery such Securities.

 

A Holder may transfer a Security only by
written application to the Registrar stating the name of the proposed transferee and otherwise complying with the terms of this
Indenture. No such transfer shall be effected until, and such transferee shall succeed to the rights of a Holder only upon, final
acceptance and registration of the transfer by the Registrar in the Security Register. Prior to the registration of any transfer
by a Holder as provided herein, the Company, the Guarantors, if any, and the Trustee or any of their respective agents shall treat
the person in whose name the Security is registered as the owner thereof for all purposes whether or not the Security shall be
overdue, and neither the Company, the Guarantors, if any, the Trustee, nor any such agent shall be affected by notice to the contrary.
Furthermore, any Holder of a Global Security shall, by acceptance of such Global Security, agree that transfers of beneficial interests
in such Global Security may be effected only through a book entry system maintained by the Depository (or its nominee) and that
ownership of a beneficial interest in the Security shall be required to be reflected in a book entry. When Securities are presented
to the Registrar or a co-Registrar with a request to register the transfer or to exchange them for an equal Principal Amount of
Securities of other authorized denominations, the Registrar shall register the transfer or make the exchange as requested if the
requirements for such transactions set forth herein are met. To permit registrations of transfers and exchanges, the Company shall
execute the Securities, the applicable Guarantors, if any, shall execute the Guarantees endorsed thereon and the Trustee shall
authenticate Securities at the Registrar’s request.

 

The Company may require payment of a sum
sufficient to cover any tax or other governmental charge that may be imposed in connection with any exchange or registration of
transfer of Securities (other than any such transfer taxes or other similar governmental charge payable upon exchanges pursuant
to Section 3.11, 9.05 or 11.03). No service charge to any Holder shall be made for any such transaction.

 

The Company shall not be required to exchange
or register a transfer of (a) any Securities of any series for a period of 15 calendar days next preceding the first
mailing of notice of redemption of Securities of that series to be redeemed, or (b) any Securities of any series selected,
called or being called for redemption except, in the case of any Security of any series where public notice has been given that
such Security is to be redeemed in part, the portion thereof not so to be redeemed.

 

    	 	-12-	 

     

    

 

All Securities issued upon any transfer
or exchange of Securities shall be valid obligations of the Company, evidencing the same debt, and entitled to the same benefits
under this Indenture, as the Securities surrendered upon such transfer or exchange.

 

SECTION 3.08.         Book-Entry
Provisions for Global Securities.

 

(a)          Each
Global Security initially shall (i) be registered in the name of the Depositary for such Global Securities or the nominee
of such Depositary, (ii) be delivered to the Trustee as custodian for such Depositary and (iii) bear legends as set forth
in Section 3.06.

 

Members of, or participants in, the Depositary
(“Agent Members”) shall have no rights under this Indenture with respect to any Global Security held on their behalf
by the Depositary, or the Trustee as its custodian, or under the Global Security, and the Depositary may be treated by the Company,
each Guarantor, if any, the Trustee and any of their respective agents as the absolute owner of such Global Security for all purposes
whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, each such Guarantor, the Trustee or any of
such agents from giving effect to any written certification, proxy or other authorization furnished by the Depositary or impair,
as between the Depositary and its Agent Members, the operation of customary practices governing the exercise of the rights of a
holder of any Security.

 

(b)          Transfers
of a Global Security shall be limited to transfers of such Global Security in whole, but not in part, to the Depositary for such
series, its successors or their respective nominees. The Company may at any time and in its sole discretion determine that the
Securities of a series issued in the form of one or more Global Securities shall no longer be represented by such Global Securities.
In such event, the Company will execute Securities of such series of like tenor and terms in definitive form in an aggregate Principal
Amount equal to the Principal Amount of the Global Security or Securities of such series, the applicable Guarantors, if any, shall
execute the Guarantees endorsed thereon and the Trustee, upon receipt of a Company Order, will authenticate and deliver such definitive
Securities in exchange for such Global Security or Securities. Interests of beneficial owners in a Global Security may be transferred
in accordance with the rules and procedures of the Depositary.

 

In addition, Physical Securities shall be
transferred to all beneficial owners identified by the Depositary in exchange for their beneficial interests in a Global Security,
if (i) the Depositary (A) notifies the Company that it is unwilling or unable to continue as Depositary for such Global
Security, and a successor depositary is not appointed by the Company within 90 calendar days of such notice, or (B) ceases
to be qualified to serve as Depositary and a successor depositary is not appointed by the Company within 90 calendar days
of such notice, (ii) the Company executes and delivers to the Trustee a Company Order that such Global Security shall be so
transferable, registrable and exchangeable, and such transfers shall be registrable, or (iii) an Event of Default of which
the Trustee has actual notice has occurred and is continuing and the Registrar has received a request from a beneficial owner to
issue such Physical Securities, and if the Trustee is the Registrar, a Company Order or written confirmation from the Depositary
identifying the beneficial owner.

 

(c)          Any
beneficial interest in one of the Global Securities that is transferred to a person who takes delivery in the form of an interest
in the other Global Security will, upon transfer, cease to be an interest in such Global Security and become an interest in the
other Global Security and, accordingly, will thereafter be subject to all transfer restrictions, if any, and other procedures applicable
to beneficial interests in such other Global Security for as long as it remains such an interest.

 

(d)          In
connection with any transfer of a portion of the beneficial interests in a Global Security to beneficial owners pursuant to paragraph
(b) of this Section 3.08, the Registrar shall reflect on its books and records the date and a decrease in the Principal
Amount of such Global Security in an amount equal to the Principal Amount of the beneficial interest in such Global Security to
be transferred, and the Company shall execute, and the Trustee shall authenticate and make available for delivery, one or more
Physical Securities of like tenor and amount.

 

(e)          In
connection with the transfer of an entire Global Security to beneficial owners pursuant to paragraph (b) of this Section,
such Global Security shall be deemed to be surrendered to the Trustee for cancellation, and the Company shall execute, and upon
receipt of a Company Order the Trustee shall authenticate and deliver, to each beneficial owner identified by the Depositary in
exchange for its beneficial interest in such Global Security, an equal Principal Amount of Physical Securities of authorized denominations.

 

    	 	-13-	 

     

    

 

(f)          The
registered holder of a Global Security may grant proxies and otherwise authorize any person, including Agent Members and persons
that may hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the
Securities of such series.

 

SECTION 3.09.         Mutilated,
Defaced, Destroyed, Lost and Stolen Securities. In case any temporary or definitive Security shall become mutilated, defaced
or be apparently destroyed, lost or stolen, the Company in its discretion may execute a new Security of the same series bearing
a number not contemporaneously outstanding, the applicable Guarantors, if any, shall execute the Guarantees endorsed thereon and,
upon the written request of any officer of the Company and delivery to the Trustee of all documents and certificates as required
by this Indenture, the Trustee shall authenticate and make available for delivery such Security, in exchange and substitution
for the mutilated or defaced Security, or in lieu of and substitution for the Security so apparently destroyed, lost or stolen.
In every case the applicant for a substitute Security shall furnish to the Company, each Guarantor, if any, the Trustee and any
of their respective agents, such security or indemnity as may be required by each of them to indemnify and defend and to save
each of them harmless and, in every case of destruction, loss or theft evidence to their satisfaction of the apparent destruction,
loss or theft of such Security and of the ownership thereof.

 

Upon the issuance of any substitute Security,
the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation
thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. In case any Security which
has matured or is about to mature, or has been called for redemption in full, shall become mutilated or defaced or be apparently
destroyed, lost or stolen, the Company may, instead of issuing a substitute Security of the same series, pay or authorize the payment
of the same (without surrender thereof except in the case of a mutilated or defaced Security), if the applicant for such payment
shall furnish to the Company, each Guarantor, if any, the Trustee and any of their respective agents such Security or indemnity
as any of them may require to save each of them harmless from all risks, however remote, and, in every case of apparent destruction,
loss or theft, the applicant shall also furnish to the Company, each such Guarantor, the Trustee and any of such agents evidence
to their satisfaction of the apparent destruction, loss or theft of such Security and of the ownership thereof.

 

Every substitute Security and the Guarantee
endorsed thereon, if any, issued pursuant to the provisions of this Section by virtue of the fact that any Security is apparently
destroyed, lost or stolen shall constitute an additional contractual obligation of the Company and any Guarantor, as applicable,
whether or not the apparently destroyed, lost or stolen Security shall be at any time enforceable by anyone and shall be entitled
to all the benefits of (but shall be subject to all the limitations of rights set forth in) this Indenture equally and proportionately
with any and all other Securities and the Guarantees endorsed thereon, if any, duly authenticated and delivered hereunder. All
Securities shall be held and owned upon the express condition that, to the extent permitted by law, with respect to the holder
of a substitute Security, the foregoing provisions are exclusive with respect to the replacement or payment of mutilated, defaced,
or apparently destroyed, lost or stolen Securities and shall preclude any and all other rights or remedies notwithstanding any
law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of negotiable instruments
or other securities without their surrender.

 

SECTION 3.10.         Cancellation
of Securities. All Securities surrendered for payment, redemption, registration of transfer or exchange, if surrendered to
the Company, any Guarantor, the Trustee or any of their respective agents, shall be delivered to the Trustee for cancellation
or, if surrendered to the Trustee, shall be cancelled by it; and no Securities shall be issued in lieu thereof except as expressly
permitted by any of the provisions of this Indenture. The Trustee shall dispose of cancelled Securities in accordance with its
customary procedures. If the Company or any Guarantor shall acquire any of the Securities, such acquisition shall not operate
as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to
the Trustee for cancellation.

 

    	 	-14-	 

     

    

 

SECTION 3.11.         Temporary
Securities. Pending the preparation of definitive Securities of any series, the Company may execute and the Trustee shall
authenticate and make available for delivery temporary Securities of such series (printed, lithographed, typewritten or otherwise
reproduced, in each case in form satisfactory to the Trustee). Temporary Securities shall be issuable as registered Securities
of such series without coupons, of any authorized denomination, and substantially in the form of the definitive Securities of
such series, and if the Securities are to be guaranteed, having endorsed thereon the Guarantees executed by each Guarantor, but
in all cases with such appropriate omissions, insertions and variations as may be appropriate for temporary Securities, all as
may be determined by the Company and the Guarantors, if any, with the concurrence of the Trustee. Temporary Securities may contain
such reference to any provisions of this Indenture as may be appropriate. Every temporary Security shall be executed by the Company
and endorsed by each Guarantor, if any, and be authenticated by the Trustee upon the same conditions and in substantially the
same manner, and with like effect, as the definitive Securities of such series. Without unreasonable delay the Company shall execute
and shall furnish definitive Securities of such series and thereupon temporary Securities of such series may be surrendered in
exchange therefor without charge at each office or agency to be maintained by the Company for the purpose pursuant to Section 4.02,
and upon delivery to the Trustee of all documents and certificates as required by this Indenture, the Trustee shall authenticate
and make available for delivery in exchange for such temporary Securities a like aggregate principal amount of definitive Securities
of such series of authorized denominations, and if the Securities are guaranteed, having endorsed thereon the Guarantees executed
by each Guarantor. Until so exchanged the temporary Securities of such series shall be entitled to the same benefits under this
Indenture as definitive Securities of such series.

 

SECTION
3.12.         CUSIP and ISIN Numbers. The Company in issuing the
Securities of any series may use a “CUSIP” and “ISIN” number (if then generally in use), and, if so,
the Trustee shall use the CUSIP numbers or ISIN numbers, as the case may be, in notices of redemption or exchange as a
convenience to Holders of such series; provided that any such notice shall state that no representation is made as to
the correctness of such numbers either as printed on the Securities or as contained in any notice of redemption or exchange
and that reliance may be placed only on the other identification numbers printed on the Securities and any such redemption
shall not be affected by any defect in or omission of such numbers. The Company shall promptly notify the Trustee of any
change in the CUSIP numbers or ISIN numbers.

 

ARTICLE 4

CERTAIN COVENANTS

 

SECTION 4.01.         Payment
of Principal, Premium and Interest on Securities. The Company, for the benefit of each series of the Securities, will duly
and punctually pay or cause to be paid the principal of and any premium and interest on the Securities of that series in accordance
with the terms of such Securities and this Indenture.

 

SECTION 4.02.         Maintenance
of Office or Agency. The Company will maintain a Payment Office where Securities may be presented or surrendered for payment,
where Securities may be surrendered for registration of transfer or exchange, and where notices and demands to or upon the Company
in respect of the Securities and this Indenture may be served. The Company will give prompt written notice to the Trustee of the
location, and any change in the location of, such office or agency. If at any time the Company shall fail to maintain any such
required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices
and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby initially appoints the
Trustee at its office or agency as its agent to receive all such presentations, surrenders, notices and demands.

 

The Company may also from time to time designate
one or more other offices or agencies where the Securities of one or more series may be presented or surrendered for any or all
such purposes and may from time to time rescind such designations; provided that no such designation or rescission shall
in any manner relieve the Company of its obligation to maintain an office or agency in accordance with the requirements set forth
above for Securities of any series for such purposes. The Company will give prompt written notice to the Trustee of any such designation
or rescission and of any change in the location of any such other office or agency.

 

    	 	-15-	 

     

    

 

SECTION 4.03.         Money
for Securities Payments to be Held in Trust.

 

(a)          If
the Company shall at any time act as its own Paying Agent with respect to any series of Securities, it will, on or before each
due date of the principal of or any premium or interest on any of the Securities of that series, segregate and hold in trust for
the benefit of the Persons entitled thereto a sum sufficient to pay the principal and any premium and interest so becoming due
until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee
of its action or failure so to act.

 

(b)          Whenever
the Company shall have one or more Paying Agents for any series of Securities, it will, prior to each due date of the principal
of or any premium or interest on any Securities of that series, deposit with a Paying Agent a sum sufficient to pay such amount,
such sum to be held as provided by the Trust Indenture Act, and (unless such Paying Agent is the Trustee) the Company will promptly
notify the Trustee of its action or failure so to act.

 

(c)          The
Company will cause each Paying Agent for any series of Securities (other than the Trustee) to execute and deliver to the Trustee
an instrument in which such Paying Agent will agree with the Trustee, subject to the provisions of this Section 4.03, that
such Paying Agent will (i) comply with the provisions of the Trust Indenture Act applicable to it as a Paying Agent; (ii) hold
all sums held by it for the payment of the principal of (and premium, if any) or interest, if any, on the Securities of that series
in trust for the benefit of the Holders until such sums shall be paid to such Holders or otherwise disposed of as herein provided;
(iii) give the Trustee notice of any Default by the Company or any Guarantor (or any other obligor upon the Securities) in
the making of any payment of principal (and premium, if any) or interest, if any, on the Securities of that series; and (iv) during
the continuance of any Default by the Company (or any other obligor upon the Securities of that series) in the making of any payment
in respect of the Securities of that series, and upon the written request of that Trustee, forthwith pay to the Trustee all sums
held in trust by such Paying Agent for payment in respect of the Securities of that series.

 

(d)          The
Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose,
pay, or by Company Order direct any Paying Agent to pay, to the Trustee all sums held in trust by the Company or such Paying Agent,
such sums to be held by the Trustee upon the same trusts as those upon which such sums were held by the Company or such Paying
Agent; and, upon such payment by any Paying Agent to the Trustee, such Paying Agent will be released from all further liability
with respect to such money.

 

(e)          Any
money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal of
or any premium or interest on any Security of any series and remaining unclaimed for two years after such principal, premium, or
interest has become due and payable and was deposited with the Paying Agent will be paid to the Company upon a Company Request
(or, if then held by the Company, will be discharged from such trust) subject to any applicable abandoned property law; and the
Holder of such Security will thereafter, as an unsecured general creditor, look only to the Company for payment thereof, and all
liability of the Trustee or such Paying Agent with respect to such trust money will thereupon cease.

 

SECTION 4.04.         Existence.
Subject to Article 10, the Company will do or cause to be done all things necessary to preserve and keep in full force and
effect its existence and rights (charter and statutory); provided that the Company will not be required to preserve any
such right or franchise if the Board of Directors determines that the preservation thereof is no longer desirable in the conduct
of the business of the Company and that the loss thereof will not be disadvantageous in any material respect to the Holders.

 

SECTION 4.05.         Statement
by Officers as to Default. The Company and, to the extent required by the TIA, each Guarantor, if any, will deliver to the
Trustee, within 120 calendar days after the end of each fiscal year of the Company ending after the first date any series of Securities
issued under this Indenture is outstanding, a certificate signed by the principal executive officer, principal financial officer
or principal accounting officer of the Company or such Guarantor stating whether or not to the knowledge of such person after
due inquiry the Company or such Guarantor is in default in the performance and observance of any of the terms, provisions, and
conditions of this Indenture (without regard to any period of grace or requirement of notice provided hereunder) and, if the Company
or such Guarantor is in default, specifying all such defaults and the nature and status thereof of which such person may have
such knowledge. The Company or such Guarantor shall deliver to the Trustee, as soon as possible and in any event within seven
calendar days after any such aforementioned officer of the Company or such Guarantor becomes aware of the occurrence of any Event
of Default or an event which, with notice or the lapse of time or both, would constitute an Event of Default, an Officers’
Certificate setting forth the details of such Event of Default or default and the action which the Company or such Guarantor proposes
to take with respect thereto.

 

    	 	-16-	 

     

    

 

SECTION 4.06.         Waiver
of Certain Covenants. The Company and each Guarantor, if any, may omit in any particular instance to comply with any term,
provision, or condition set forth in this Indenture or any applicable supplemental indenture, with respect to the Securities of
any series, if the Holders of a majority in Principal Amount of all outstanding Securities of such series shall, by act of such
Holders in accordance with Section 7.01, either waive such compliance in such instance or generally waive compliance with
such term, provision, or condition in accordance with Article 9 and Section 5.07, but no such waiver will extend to or affect
such term, provision or condition except to the extent so expressly waived, and, until such waiver shall become effective, the
obligations of the Company and such Guarantor and the duties of the Trustee in respect of any such term, provision, or condition
will remain in full force and effect.

 

ARTICLE 5

REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT

 

SECTION 5.01.         Events
of Default. Each of the following events constitutes an “Event of Default” wherever used herein with respect to
Securities of any series:

 

(a)          default
for 30 calendar days in the payment when due of interest on the Securities of that series;

 

(b)          default
in payment when due of the principal (whether at Stated Maturity, upon redemption (if applicable), upon any required repurchase
by the Company (if applicable) or otherwise) of or premium, if any, on the Securities of that series;

 

(c)          default
by the Company or any Guarantor of such series of Securities in the observance or performance of any other covenant or agreement
contained in this Indenture or as specified pursuant to Section 3.01 (other than a default referred to in clauses (a) or (b) above,
or an agreement, covenant or provision that has expressly been included in this Indenture solely for the benefit of one or more
series of Securities other than that series) which default continues for a period of 60 calendar days after the Company or such
Guarantor receives written notice specifying the default (and demanding that such default be remedied) from the Trustee or the
Holders of at least 25% of the Principal Amount of Securities of that series then outstanding (with a copy to the Trustee if given
by Holders) (except in the case of a default with respect to Section 10.01 of this Indenture, which will constitute an Event of
Default with such notice requirement but without such passage of time requirement).

 

(d)          the
entry by a court having jurisdiction in the premises of (i) a decree or order for relief in respect of the Company or a Guarantor
of such series of Securities in an involuntary case or proceeding under any applicable federal or state bankruptcy, insolvency,
reorganization, or other similar law or (ii) a decree or order adjudging the Company or such Guarantor bankrupt or insolvent,
or approving as properly filed a petition seeking reorganization, arrangement, adjustment, or composition of or in respect of the
Company or such Guarantor under any applicable federal or state law, or appointing a custodian, receiver, liquidator, assignee,
trustee, sequestrator, or other similar official of the Company or such Guarantor or of any substantial part of its property, or
ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order for relief or any such other
decree or order unstayed and in effect for a period of 60 consecutive calendar days;

 

    	 	-17-	 

     

    

 

(e)          the
commencement by the Company or a Guarantor of such series of Securities of a voluntary case or proceeding under any applicable
federal or state bankruptcy, insolvency, reorganization, or other similar law or of any other case or proceeding to be adjudicated
bankrupt or insolvent, or the consent by it to the entry of a decree or order for relief in respect of the Company or such Guarantor
in an involuntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization, or other similar
law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or
answer or consent seeking reorganization or relief with respect to the Company or such Guarantor under any applicable federal or
state bankruptcy, insolvency, reorganization, or other similar law, or the consent by it to the filing of such petition or to the
appointment of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator, or other similar official
of the Company or such Guarantor or of any substantial part of its property pursuant to any such law, or the making by it of an
assignment for the benefit of creditors, or the admission by it in writing of its inability to pay its debts generally as they
become due, or the taking of corporate action by the Company or such Guarantor in furtherance of any such action;

 

(f)          any
Guarantee relating to such series Securities shall cease to be in full force and effect (other than in accordance with the terms
of this Indenture) or any Guarantor denies or disaffirms its obligations under its Guarantee; or

 

(g)          any
other Event of Default with respect to Securities of that series as specified pursuant to Section 3.01, which shall not have been
remedied within the specified period after written notice, as specified in Section 5.01(c).

 

SECTION 5.02.         Acceleration.

 

(a)          If
any Event of Default (other than an Event of Default specified in clause (d) or (e) of Section 5.01) occurs and
is continuing with respect to Securities of any series, the Trustee by written notice to the Company or the Holders of at least
25% in aggregate Principal Amount of the then outstanding Securities of that series by written notice to the Company and the Trustee,
may declare the unpaid principal of, premium, if any, and any accrued and unpaid interest on all the Securities of the affected
series to be due and payable immediately. Except as set forth above, upon such declaration the principal of, premium, if any, and
interest shall be due and payable immediately. If an Event of Default specified in clause (d) or (e) of Section 5.01
occurs with respect to the Company or any Guarantor, the unpaid principal of, premium, if any, and any accrued and unpaid interest
on all the Securities shall ipso facto become and be immediately due and payable without further action or notice on the
part of the Trustee or any Holder.

 

(b)          At
any time after such a declaration of acceleration with respect to the Securities of any series has been made and before a judgment
or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article 5 provided, the Holders
of a majority in Principal Amount of the outstanding Securities of such series, by written notice to the Company and the Trustee,
may rescind and annul such declaration and its consequences if (i) the Company or a Guarantor has paid or deposited with the
Trustee a sum sufficient to pay (A) all overdue interest on all of the Securities of that series, (B) the principal of
(and premium, if any, on) Securities of that series which has become due otherwise than by such declaration of acceleration and
any interest thereon at the rate or rates prescribed therefor in the Securities of that series, (C) to the extent that payment
of such interest is lawful, interest upon overdue interest at the rate or rates prescribed therefor in the Securities of that series,
and (D) all sums paid or advanced by the Trustee hereunder and the reasonable compensation, expenses, disbursements and advances
of the Trustee and its agents and counsel and (ii) all Events of Default with respect to the Securities of that series, other
than the non-payment of the principal of the Securities of that series which have become due solely by such declaration of acceleration,
have been cured or waived as provided in Section 5.04. No such rescission will affect any subsequent default or impair any
right consequent thereon.

 

SECTION 5.03.         Other
Remedies. If an Event of Default with respect to Securities of any series occurs and is continuing, the Trustee may pursue
any available remedy to collect the payment of principal or interest on the Securities of such series or to enforce the performance
of any provision of the Securities of such series or this Indenture.

 

The Trustee may maintain a proceeding even
if it does not possess any of the Securities of such series or does not produce any of them in the proceeding and any such proceeding
instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall,
after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents
and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.
A delay or omission by the Trustee or any Holder in exercising any right or remedy accruing upon an Event of Default shall not
impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. All remedies are cumulative to the
extent permitted by law.

 

    	 	-18-	 

     

    

 

SECTION 5.04.         Waiver
of Past Defaults. The Holders of not less than a majority in aggregate Principal Amount of the Securities of any series then
outstanding by written notice to the Trustee may on behalf of the Holders of all of the Securities of such series waive any existing
Default or Event of Default and its consequences under this Indenture except a continuing Default or Event of Default in the payment
of the principal (whether at Stated Maturity, upon redemption (if applicable), upon any required repurchase by the Company (if
applicable) or otherwise) of (and premium, if any) or interest, if any, on any Security of such series or, in the case of the
Securities of any series that are convertible or exchangeable, in the payment or delivery of any consideration due upon conversion
or exchange of the Securities of that series (if applicable). The Company may, but shall not be obligated to, fix a record date
for the purpose of determining the Persons entitled to waive any past Default hereunder. If a record date is fixed, the Holders
on such record date, or their duly designated proxies, and only such Persons, shall be entitled to waive any Default hereunder,
whether or not such Holders remain Holders after such record date. Upon any such waiver, such Default shall cease to exist, and
any Event of Default arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no such waiver
shall extend to any subsequent or other Default or impair any right consequent thereon.

 

SECTION 5.05.         Control
by Majority. With respect to the Securities of any series, the Holders of a majority in aggregate Principal Amount of the
then outstanding Securities of that series may direct the time, method and place of conducting any proceeding for any remedy available
to the Trustee or exercising any trust or power conferred on it. However, the Trustee may refuse to follow any direction that
conflicts with law or this Indenture, that the Trustee in good faith determines may be unduly prejudicial to the rights of other
Holders of that series or that may involve or cause the Trustee any potential liability. The Trustee may take any other action
which it deems proper which is not inconsistent with any such direction.

 

SECTION 5.06.         Limitation
on Suits. A Holder of any Security of any series may pursue a remedy with respect to this Indenture or the Securities of the
applicable series only if:

 

(a)          the
Holder gives to the Trustee written notice of a continuing Event of Default with respect to that series;

 

(b)          the
Holders of at least 25% in aggregate Principal Amount of the then outstanding Securities of that series make a written request
to the Trustee to pursue the remedy;

 

(c)          such
Holder or Holders provide to the Trustee indemnity satisfactory to the Trustee against any loss, liability or expense in connection
with the pursuance of such remedy;

 

(d)          during
the 60-day period specified in (e) below, the Holders of a majority in aggregate Principal Amount of the then outstanding
Securities of such series do not give the Trustee a direction inconsistent with the request; and

 

(e)          the
Trustee does not comply with the request within 60 calendar days after receipt of the notice, request and the offer of indemnity.

 

Holders shall not have any right in any
manner whatever by virtue of, or by availing of, any provision of this Indenture or any Security to affect, disturb or prejudice
the rights of any other such Holders or Holders of Securities of any other series, or to obtain or to seek to obtain priority or
preference over any other Holders or to enforce any right under this Indenture, except in the manner herein provided and for the
equal and ratable benefit of all such Holders.

 

SECTION 5.07.         Rights
of Holders to Receive Payment. Notwithstanding any other provision of this Indenture, the right of any Holder to receive payment
of principal (whether at Stated Maturity, upon redemption (if applicable), upon any required repurchase by the Company (if applicable)
or otherwise) of (and premium, if any) and interest, if any, on any Security or, if applicable, payment or delivery of any consideration
due upon conversion or exchange of any Security, in each case, on or after the respective due dates expressed in such Security,
or to bring suit for the enforcement of any such payment or delivery on or after such respective dates, shall not be impaired
or affected without the consent of the Holder.

 

    	 	-19-	 

     

    

 

SECTION 5.08.         Collection
Suit by Trustee. If an Event of Default specified in Sections 5.01(a) and 5.01(b) occurs and is continuing, the Trustee is
authorized to recover judgment in its own name and as trustee of an express trust against the Company, any Guarantor or any other
obligor for the whole amount of principal (and premium, if any) and interest, if any, remaining unpaid on any Securities of such
series and interest on overdue principal and, to the extent lawful, interest and such further amount as shall be sufficient to
cover amounts due the Trustee under Section 6.07 hereof, including the costs and expenses of collection, including the reasonable
compensation, expenses, disbursements and advances of the Trustee, its agents and counsel.

 

SECTION 5.09.         Trustee
May File Proofs of Claim. The Trustee is authorized to file such proofs of claim and other papers or documents as may be necessary
or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements
and advances of the Trustee, its agents and counsel) and the Holders allowed in any judicial proceedings relative to the Company
or any Guarantor (or any other obligor upon the Securities), its creditors or its property and shall be entitled and empowered
to collect, receive and distribute any money or other property payable or deliverable on any such claims and any custodian in
any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee, and in the event that the
Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it for the
reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due
the Trustee under Section 6.07 hereof. To the extent that the payment of any such compensation, expenses, disbursements and
advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 6.07 hereof out of the
estate in any such proceeding, shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be
paid out of, any and all distributions, dividends, money, securities and other properties which the Holders may be entitled to
receive in such proceeding whether in liquidation or under any plan of reorganization or arrangement or otherwise. Nothing herein
contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan
of reorganization, arrangement, adjustment or composition affecting the Securities of any series or the rights of any Holder thereof,
or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.

 

SECTION 5.10.         Priorities.
If the Trustee collects any money pursuant to this Article, it shall pay out the money in the following order:

 

First: to the Trustee, its agents
and attorneys for amounts due under Section 6.07, including payment of all compensation, expense and liabilities incurred,
and all advances made, by the Trustee and the costs and expenses of collection;

 

Second: to Holders for amounts
due and unpaid on the Securities of any series for principal (and premium, if any) and interest, if any, ratably, without preference
or priority of any kind, according to the amounts due and payable on the Securities of such series for principal (and premium,
if any) and interest, if any, respectively; and

 

Third: to the Company or, to the
extent the Trustee collects any amount pursuant to Section 2.02 hereof from a Guarantor, to such Guarantor, or to such party as
a court of competent jurisdiction shall direct.

 

The Trustee may fix a record date and payment
date for any payment to Holders pursuant to this Section 5.10 upon seven calendar days prior notice to the Company.

 

SECTION 5.11.         Undertaking
for Costs. In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee
for any action taken or omitted by it as a Trustee, a court in its discretion may require the filing by any party litigant in
the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including
reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to the merits and good
faith of the claims or defenses made by the party litigant. This Section 5.11 does not apply to a suit by the Trustee, a suit
by a Holder of Securities of the affected series pursuant to Section 5.07 hereof, a suit by Holders of more than 10% in aggregate
Principal Amount of the then outstanding Securities of any series in the case of any suit relating to or arising under clause
(a), (b), (c), (f) or (g) of Section 5.01, or a suit by Holders of more than 10% in aggregate Principal Amount
of the then outstanding Securities of all series in the case of any suit relating to or arising under clause (d) or (e) of
Section 5.01.

 

    	 	-20-	 

     

    

 

SECTION 5.12.         Restoration
of Rights and Remedies. If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this
Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee
or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, any Guarantor, the
Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights
and remedies of the Trustee and the Holders shall continue as though no such proceeding has been instituted.

 

SECTION 5.13.         Rights
and Remedies Cumulative. Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed,
lost or stolen Securities in the last paragraph of Section 3.09, no right or remedy herein conferred upon or reserved to
the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the
extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing
at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other appropriate right or remedy.

 

SECTION 5.14.         Delay
or Omission Not Waiver. No delay or omission of the Trustee or of any Holder of Securities of any series to exercise any right
or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of
Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders may
be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.

 

ARTICLE 6

THE TRUSTEE

 

SECTION 6.01.         Duties
and Responsibilities of the Trustee; During Default; Prior to Default. The Trustee, with respect to the Securities of any
series, prior to the occurrence of an Event of Default with respect to the Securities of such series and after the curing or waiving
of all Events of Default with respect to the Securities of such series which may have occurred, undertakes to perform such duties
and only such duties with respect to such series as are specifically set forth in this Indenture. In case an Event of Default
with respect to the Securities of a series has occurred (and is continuing which has not been cured or waived) the Trustee shall
exercise such of the rights and powers vested in it by this Indenture with respect to such series, and use the same degree of
care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s
own affairs.

 

No provision of this Indenture shall be
construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act or its own willful
misconduct, provided that:

 

(a)          the
duties and obligations of the Trustee shall be determined solely by the express provisions of this Indenture, and the Trustee shall
not be liable except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no
implied covenants or obligations shall be read into this Indenture against the Trustee;

 

(b)          in
the absence of bad faith on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon any statements, certificates or opinions furnished to the Trustee and conforming
to the requirements of this Indenture; but in the case of any such statements, certificates or opinions which by any provision
hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine
whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of any calculation
or facts stated therein);

 

    	 	-21-	 

     

    

 

(c)          the
Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it shall be conclusively
determined by a court of competent jurisdiction or by such other means as may be agreed by the Company and the Trustee at the time
of determination that the Trustee was negligent in ascertaining the pertinent facts; and

 

(d)          the
Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with a Company
Order or the direction of the Holders given as provided in Section 5.05 or otherwise exercising any trust or power conferred
upon the Trustee, under this Indenture.

 

None of the provisions contained in this
Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any potential or actual liability (financial
or otherwise) in the performance of any of its duties or in the exercise of any of its rights or powers, if there shall be reasonable
ground for believing that the repayment of such funds or adequate indemnity against such liability is not assured to it. This Section 6.01
is in furtherance of and subject to Sections 315 and 316 of the Trust Indenture Act.

 

Whether or not therein expressly so provided,
every provision of this Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee
shall be subject to the provisions of this Article 6.

 

SECTION 6.02.         Certain
Rights of the Trustee. In furtherance of and subject to the Trust Indenture Act, and subject to Section 6.01:

 

(a)          the
Trustee may conclusively rely and shall be protected in acting or refraining from acting upon any resolution, Officers’ Certificate,
Opinion of Counsel or any other certificate, statement, instrument, opinion, report, notice, request, consent, order, bond, debenture,
note, coupon, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties;

 

(b)          any
request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an Officers’ Certificate
(unless other evidence in respect thereof be herein specifically prescribed) and the Trustee may request and be entitled to receive
an Officers’ Certificate before acting or refraining from acting with respect to such request, direction, order or demand;
and any resolution of the Board of Directors of the Company or a Guarantor, if any, may be evidenced to the Trustee by a copy thereof
certified by the Secretary or an Assistant Secretary of the Company or that Guarantor;

 

(c)          the
Trustee may consult with counsel of its selection and any advice or Opinion of Counsel shall be full and complete authorization
and protection in respect of any action taken, suffered or omitted to be taken by it hereunder in good faith and in accordance
with such advice or Opinion of Counsel;

 

(d)          the
Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order
or direction of any of the Holders of the Securities of any series pursuant to the provisions of this Indenture, unless such Holders
shall have offered and provided to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities
which might be incurred therein or thereby;

 

(e)          the
Trustee shall not be liable for any action taken or omitted by it in good faith and believed by it to be authorized or within the
discretion, rights or powers conferred upon it by this Indenture;

 

(f)          the
Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate,
statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon,
security, or other paper or document unless requested in writing so to do by the Holders of not less than a majority in
aggregate Principal Amount of the Securities of any series then outstanding; provided that, if the payment within a
reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such
investigation is, in the opinion of the Trustee, not assured to the Trustee by the security afforded to it by the terms of
this Indenture, the Trustee may require (and shall not be required to make such investigation unless it receives) indemnity
satisfactory to it against such expenses or liabilities as a condition to proceeding; the reasonable expenses of every such
examination shall be paid by the Company;

 

    	 	-22-	 

     

    

 

(g)          the
Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents
or attorneys not regularly in its employ and the Trustee shall not be responsible for any misconduct or negligence on the part
of any such agent or attorney appointed with due care by it hereunder;

 

(h)          the
rights, privileges, protections, immunities and benefits given to the Trustee under this Indenture, including, without limitation,
its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and
to each agent, custodian and other Person employed to act hereunder and the employees, officers and directors of the Trustee;

 

(i)          the
Trustee shall not be deemed to have knowledge of any Default or Event of Default unless a Responsible Officer of the Trustee has
received from a Holder, the Company or any Guarantor written notice of any event which is in fact such a Default or Event of Default,
as the case may be, and such notice references the Securities, this Indenture, the circumstances giving rise to such a Default
or Event of Default and that the same has occurred and is continuing; and

 

(j)          The
Trustee may request that the Company deliver an Officers’ Certificate setting forth the names of individuals and/or titles
of officers authorized at such time to take specified actions pursuant to this Indenture, which Officers’ Certificate may
be signed by any person authorized to sign an Officers’ Certificate, including any person specified as so authorized in any
such certificate previously delivered and not superseded.

 

SECTION 6.03.         Trustee
Not Responsible for Recitals, Disposition of Securities or Application of Proceeds Thereof. The recitals contained herein
and in the Securities, except the Trustee’s certificates of authentication, shall be taken as the statements of the Company,
and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representation as to the validity
or sufficiency of this Indenture or of the Securities, except that the Trustee represents, that it is duly authorized to execute
and deliver this Indenture, authenticate the Securities and perform its obligations hereunder and that the statements made by
it in a Statement of Eligibility on Form T-1 supplied to the Company, are true and accurate, subject to the qualifications set
forth therein. The Trustee shall not be liable or accountable in any manner for the use or application by the Company of any of
the Securities or of the proceeds thereof.

 

SECTION 6.04.         Trustee
and Agents May Hold Securities; Collections, Etc. The Trustee or any of its affiliates or any agent of the Company or the
Trustee, in its individual or any other capacity, may become the owner or pledgee of Securities, subject to Sections 6.10
and 6.13 with the same rights it would have if it were not the Trustee or such agent and may otherwise deal with the Company,
any Guarantor or their respective affiliates and receive, collect, hold and retain collections from the Company with the same
rights it would have if it were not the Trustee or such agent. However, in the event that the Trustee acquires any “conflicting
interest,” as defined in Section 310(b) of the Trust Indenture Act, it must eliminate such conflict within 90 calendar days,
apply to the Commission for permission to continue as trustee or resign.

 

SECTION 6.05.         Moneys
Held by Trustee. All moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for
the purposes for which they were received, but need not be segregated from other funds except to the extent required by mandatory
provisions of law. Neither the Trustee nor any agent of the Company or the Trustee shall be under any liability for interest on
any moneys received by it hereunder, except as otherwise agreed with the Company.

 

SECTION 6.06.         Notice
of Default. If any Default or any Event of Default occurs and is continuing with respect to the Securities of any series and
if such Default or Event of Default is actually known to a Responsible Officer of the Trustee, the Trustee shall mail to each
Holder of Securities of such series in the manner and to the extent provided in Trust Indenture Act Section 313(c) notice of the
Default or Event of Default (“Notice of Default”) within 90 calendar days after it occurs, unless such Default
or Event of Default has been cured; provided that, except in the case of a default in the payment of the principal (whether
at Stated Maturity, upon redemption (if applicable), upon any required repurchase by the Company (if applicable) or otherwise)
of, or interest or premium, if any, on any Security of such series, in the payment or delivery of any consideration due upon conversion
or exchange of any Security of such series (if applicable) or in the payment of any sinking fund installment with respect to Securities
of such series, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive
committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith determine that the withholding
of such notice is in the interest of the Holders of Securities of such series.

 

    	 	-23-	 

     

    

 

SECTION 6.07.         Compensation
and Indemnification of Trustee and Its Prior Claim. The Company covenants and agrees to pay to the Trustee from time to time,
and the Trustee shall be entitled to, such compensation as shall be agreed in writing between the Company and the Trustee (which
shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) and the Company covenants
and agrees to pay or reimburse the Trustee and each predecessor Trustee upon its request for all reasonable expenses, disbursements
and advances incurred or made by or on behalf of it in accordance with any of the provisions of this Indenture (including the
reasonable compensation and the expenses and disbursements of its counsel and of all agents and other persons not regularly in
its employ) except any such expense, disbursement or advance as may arise from its negligence or bad faith (as determined by a
court of competent jurisdiction in a final, non-appealable decision or by such other means as may be agreed by the Company and
the Trustee at the time of determination). The Company also covenants to indemnify the Trustee and each predecessor Trustee for,
and to hold it harmless against, any and all loss, liability, damage, claim or expense, including taxes (other than taxes based
on the income of the Trustee) incurred without negligence or bad faith on its part (as determined by a court of competent jurisdiction
in a final, non-appealable decision or by such other means as may be agreed by the Company and the Trustee at the time of determination),
arising out of or in connection with the acceptance or administration of this Indenture or the trusts hereunder and its duties
hereunder, including without limitation the costs and expenses of defending itself against or investigating any claim (whether
asserted by the Company, a Holder or any other Person). The obligations of the Company under this Section to compensate and indemnify
the Trustee and each predecessor Trustee and to pay or reimburse the Trustee and each predecessor Trustee for expenses, disbursements
and advances shall constitute additional indebtedness hereunder and shall survive the satisfaction and discharge of this Indenture.
Such financial obligations of the Company identified in this Section 6.07 shall be a senior claim to that of the Securities of
each series, and as security for such obligations, the Trustee shall have a lien prior to such Securities, upon all property and
funds held or collected by the Trustee as such, except funds held in trust for the benefit of the Holders of particular Securities,
and the Securities of each series are hereby subordinated to such senior claim. Such lien shall survive the discharge and satisfaction
of this Indenture.

 

When the Trustee incurs expenses or renders
services in connection with an Event of Default specified in Section 5.01(d) or Section 5.01(e), the expenses (including
the reasonable charges and expenses of its counsel) and the compensation for the services are intended to constitute expenses of
administration under any applicable federal or state bankruptcy, insolvency or other similar law.

 

SECTION 6.08.         Right
of Trustee to Rely on Officers’ Certificate, Etc. Subject to Sections 6.01 and 6.02, whenever in the administration
of the trusts of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior
to taking or suffering or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically
prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and
established by an Officers’ Certificate delivered to the Trustee, and such certificate, in the absence of negligence or
bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted by it under
the provisions of this Indenture upon the faith thereof.

 

SECTION 6.09.         Persons
Eligible for Appointment as Trustee. The Trustee hereunder shall at all times be a corporation, national association or other
appropriate entity having a combined capital and surplus of at least $150,000,000, and which is eligible in accordance with the
provisions of Section 310(a) of the Trust Indenture Act. If such corporation publishes reports of condition at least annually,
pursuant to law or to the requirements of a federal, state or District of Columbia supervising or examining authority, then for
the purposes of this Section, the combined capital and surplus of such corporation shall be deemed to be its combined capital
and surplus as set forth in its most recent report of condition so published.

 

    	 	-24-	 

     

    

 

SECTION 6.10.         Resignation
and Removal; Appointment of Successor Trustee.

 

(a)          The
Trustee may at any time resign with respect to the Securities of one or more series by giving written notice of resignation to
the Company and to the Holders of Securities of such series, such notice to the Holders to be given by mailing (by first class
mail) the same within 30 calendar days after such notice is given to the Company. Upon receiving such notice of resignation,
the Company shall promptly appoint a successor trustee by written instrument in duplicate, executed by authority of the Board of
Directors of the Company, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor
trustee. If no successor trustee shall have been so appointed and have accepted appointment within 30 calendar days after
the mailing of such notice of resignation, the resigning trustee may petition, at the expense of the Company, any court of competent
jurisdiction for the appointment of a successor trustee, or any Holder of the affected series who has been a bona fide holder of
the Securities of the affected series for at least six months (or since the Issue Date for such Securities if the holding period
is less than six months) may, on behalf of itself and all others similarly situated, petition any such court for the appointment
of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor
trustee.

 

(b)          In
case at any time any of the following shall occur:

 

(i)          the
Trustee shall fail to comply with the provisions of Section 310(b) of the Trust Indenture Act, after written request therefor by
the Company or by any Holder who has been a bona fide holder of Securities of the affected series for at least six months; or

 

(ii)         the
Trustee shall cease to be eligible in accordance with the provisions of Section 6.09, and shall fail to resign after written
request therefor by the Company or by any such Holder; or

 

(iii)        the
Trustee shall become incapable of acting, or shall be adjudged as bankrupt or insolvent, or a receiver or liquidator of the Trustee
or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or
affairs for the purpose of rehabilitation, conservation or liquidation;

 

then, in any such case, the Company may remove the Trustee and
appoint a successor trustee by written instrument, in duplicate, executed by authority of the Board of Directors of the Company,
one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to
Section 315(e) of the Trust Indenture Act, any Holder of the affected series who has been a bona fide holder of the Securities
of the affected series for at least six months may, on behalf of itself and all others similarly situated, petition any court of
competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon, after
such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.

 

(c)          The
Holders of a majority in aggregate Principal Amount of the Securities of any series at the time outstanding may at any time remove
the Trustee for that series and appoint a successor trustee by delivering to the Trustee so removed, to the successor trustee so
appointed and to the Company and any Guarantor the evidence provided for in Section 7.01 of the action in that regard taken
by the Holders of that series.

 

If no successor trustee shall have been
so appointed and have accepted appointment 30 calendar days after the mailing of such notice of removal, the Trustee being
removed may petition, at the expense of the Company, any court of competent jurisdiction for the appointment of a successor trustee.
Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.

 

(d)          Any
resignation or removal of the Trustee and any appointment of a successor trustee pursuant to any of the provisions of this Section 6.10
shall become effective upon acceptance of appointment by the successor trustee as provided in Section 6.11.

 

(e)          The
Company shall give notice of each resignation and each removal of the Trustee with respect to the Securities of any series and
each appointment of a successor Trustee with respect to the Securities of any series by mailing written notice of such event by
first-class mail, postage prepaid, to all Holders of Securities of such series as their names and addresses appear in the Security
Register. Each notice shall include the name of the successor Trustee with respect to the Securities of such series and the address
of its Corporate Trust Office.

 

    	 	-25-	 

     

    

 

SECTION 6.11.         Acceptance
of Appointment by Successor.

 

(a)          In
case of the appointment hereunder of a successor Trustee with respect to all Securities, every such successor Trustee so appointed
shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and
thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further
act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, on the
request of the Company or the successor Trustee, such retiring Trustee shall, upon payment of its fees, costs, expenses and other
charges, execute and deliver an instrument transferring to such successor Trustee all the rights, powers and trusts of the retiring
Trustee and shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee
hereunder.

 

(b)          In
case of the appointment hereunder of a successor Trustee with respect to the Securities of one or more (but not all) series, the
Company, any applicable Guarantor, the retiring Trustee and each successor Trustee with respect to the Securities of one or more
series shall execute and deliver an indenture supplemental hereto wherein each successor Trustee shall accept such appointment
and which (1) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each
successor Trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those
series to which the appointment of such successor Trustee relates, (2) if the retiring Trustee is not retiring with respect
to all Securities, shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers,
trusts and duties of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee
is not retiring shall continue to be vested in the retiring Trustee, and (3) shall add to or change any of the provisions
of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one
Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of
the same trust and that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or
trusts hereunder administered by any other such Trustee; and upon the execution and delivery of such supplemental indenture the
resignation or removal of the retiring Trustee shall become effective to the extent provided therein and each such successor Trustee,
without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring
Trustee with respect to the Securities of that or those series to which the appointment of such successor Trustee relates; but,
on request of the Company or any successor Trustee, such retiring Trustee shall upon payment of its fees, costs, expenses and other
charges duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee hereunder
with respect to the Securities of that or those series to which the appointment of such successor Trustee relates.

 

(c)          Upon
request of any such successor Trustee, the Company and any applicable Guarantor shall execute any and all instruments for more
fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and trusts referred to in paragraph
(a) or (b) of this Section, as the case may be.

 

(d)          No
successor Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified
and eligible under the Trust Indenture Act.

 

SECTION
6.12.         Merger, Conversion, Consolidation or Succession to Business of
Trustee. Any corporation or national association into which the Trustee may be merged or converted or with which it may
be consolidated, or to which the Trustee’s assets may be sold, or any corporation or national association resulting
from any merger, conversion, consolidation or sale to which the Trustee shall be a party or by which the Trustee’s
property may be bound, or any corporation or national association succeeding to all or substantially all the corporate trust
business of the Trustee, shall be the successor of the Trustee hereunder, provided that such entity shall be eligible
under the provisions of Section 6.09, without the execution or filing of any paper or any further act on the part of any
of the parties hereto, anything herein to the contrary notwithstanding.

 

    	 	-26-	 

     

    

 

In case at the time such successor to
the Trustee shall succeed to the trusts created by this Indenture any of the Securities shall have been authenticated but not
delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor Trustee and
deliver such Securities so authenticated; and, in case at that time any of the Securities shall not have been authenticated,
any successor to the Trustee may authenticate such Securities either in the name of any predecessor hereunder or in the name
of the successor Trustee; and in all such cases such certificate shall have the full force that it is anywhere in the
Securities or in this Indenture ; provided that the right to adopt the certificate of authentication of any
predecessor Trustee or to authenticate Securities in the name of any predecessor Trustee shall apply only to its successor or
successors by merger, conversion or consolidation.

 

SECTION 6.13.         Preferential
Collection of Claims. If the Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of
the Company (or any other obligor on the Securities), the Trustee shall be subject to the provisions of Section 311 of the
Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor). For purposes of Section 311(b)
(4) and (6) of such Act, the following terms shall mean:

 

(a)          “cash
transaction” means any transaction in which full payment for goods or securities sold is made within seven calendar days
after delivery of the goods or securities in currency or in checks or other orders drawn upon banks or bankers and payable upon
demand; and

 

(b)          “self-liquidating
paper” means any draft, bill of exchange, acceptance or obligation which is made, drawn, negotiated or incurred by the Company
for the purpose of financing the purchase, processing, manufacturing, shipment, storage or sale of goods, wares or merchandise
and which is secured by documents evidencing title to, possession of, or a lien upon, the goods, wares or merchandise or the receivables
or proceeds arising from the sale of the goods, wares or merchandise previously constituting the security, provided the security
is received by the Trustee simultaneously with the creation of the creditor relationship with the Company arising from the making,
drawing, negotiating or incurring of the draft, bill of exchange, acceptance or obligation.

 

SECTION 6.14.         Communications
with the Trustee. Any and all notices, certificates, opinions or filings with the Commission required or permitted to be provided
by the Company to the Trustee under this Indenture shall be in writing and shall be personally delivered, sent via an internationally
recognized overnight delivery service or sent by facsimile or electronic transmission to the address or telecopy number of the
Corporate Trust Office.

 

SECTION 6.15.         Paying
Agent/Registrar. If the Trustee is acting as Paying Agent and/or Registrar hereunder, the rights and protections afforded
to the Trustee under this Article 6 will also be afforded to the Paying Agent and/or the Registrar.

 

ARTICLE 7

CONCERNING THE HOLDERS

 

SECTION 7.01.         Evidence
of Action Taken by Holders. Any request, demand, authorization, direction, notice, consent, waiver or other action provided
by this Indenture to be given or taken by Holders of Securities of any series may be embodied in and evidenced (a) by one
or more instruments of substantially similar tenor signed by such Holders in person or by agent duly appointed in writing, (b) by
the record of the Holders of Securities of such series voting in favor thereof at any meeting of Holders duly called and held
in accordance with the provisions of Article 8, or (c) by a combination of such instrument or instruments and any such
record of such a meeting of Holders; and, except as herein otherwise expressly provided, such action shall become effective when
such instrument or instruments are delivered to the Trustee and, where it is hereby expressly required, to the Company and each
Guarantor, if any. Proof of execution of any instrument or of a writing appointing any such agent shall be sufficient for any
purpose of this Indenture and (subject to Sections 6.01 and 6.02) conclusive in favor of the Trustee, the Company and each
Guarantor, if any, if made in the manner provided in this Article.

 

    	 	-27-	 

     

    

 

SECTION 7.02.         Proof
of Execution of Instruments and of Holding of Securities; Record Date. Subject to Sections 6.01 and 6.02, the execution
of any instrument by a Holder or its agent or proxy may be proved in accordance with such reasonable rules and regulations as
may be prescribed by the Trustee or in such manner as shall be satisfactory to the Trustee. The holding of Securities shall be
proved by the Security Register or by a certificate of the Registrar thereof. The Company may set a record date for purposes of
determining the identity of Holders of Securities entitled to vote or consent to any action referred to in Section 7.01,
which record date may be set at any time or from time to time by notice to the Trustee, for any date or dates (in the case of
any adjournment or resolicitation) not more than 90 calendar days nor less than 20 calendar days prior to the proposed
date of such vote or consent, and thereafter, notwithstanding any other provisions hereof, only Holders of Securities of record
on such record date shall be entitled to so vote or give such consent or to withdraw such vote or consent.

 

SECTION 7.03.         Who
May Be Deemed Owners of Securities. The Company, each Guarantor, if any, the Trustee, any Paying Agent and any Registrar may
deem and treat the person in whose name any Security of any series shall be registered in the Security Register on the applicable
record date as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notation
of ownership or other writing thereon) for the purpose of receiving payment of or on account of the principal of (and premium,
if any) and interest, if any, on such Security and for all other purposes; and none of the Company, any Guarantor, the Trustee,
any Paying Agent or any Registrar shall be affected by any notice to the contrary. All such payments so made to, or upon the order
of, any Holders shall be valid, and, to the extent of the sum or sums so paid, effectual to satisfy and discharge the liability
of moneys payable upon any such Security.

 

SECTION 7.04.         Securities
Owned by Company Deemed Not Outstanding. In determining whether the Holders of the requisite aggregate Principal Amount of
Securities of any series have concurred in any direction, consent or waiver under this Indenture, Securities of such series which
are owned by the Company, any Guarantor with respect to such series or any other obligor on the Securities of such series or by
any person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company, any
such Guarantor or any other obligor on the Securities of such series shall be disregarded and deemed not to be outstanding for
the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected in relying
on any such direction, consent or waiver only Securities which a Responsible Officer of the Trustee actually knows are so owned
shall be so disregarded. Securities so owned which have been pledged in good faith may be regarded as outstanding if the pledgee
establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Securities and that the
pledgee is not the Company, any Guarantor or any other obligor upon the Securities or any person directly or indirectly controlling
or controlled by or under direct or indirect common control with the Company, any Guarantor or any other obligor on the Securities.
In case of a dispute as to such right, the advice of counsel shall be full protection in respect of any decision made by the Trustee
in accordance with such advice. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officers’
Certificate listing and identifying all Securities of any series, if any, known by the Company to be owned or held by or for the
account of any of the above-described persons; and, subject to Sections 6.01 and 6.02, the Trustee shall be entitled to accept
such Officers’ Certificate as conclusive evidence of the facts therein set forth and of the fact that all Securities of
such series not listed therein are outstanding for the purpose of any such determination.

 

SECTION 7.05.         Record
Date for Action by Holders. Whenever in this Indenture it is provided that Holders of a specified percentage in aggregate
principal amount of the Securities of any series may take any action (including the making of any demand or request, the giving
of any direction, notice, consent or waiver or the taking of any other action), other than any action taken at a meeting of Holders
of such series called pursuant to Article 8, the Company may, but shall not be obligated to, fix a record date, which need
not be the date provided in TIA Section 316(c) to the extent it would otherwise be applicable, for the purpose of determining
the Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant
to this Indenture. If a record date is fixed, then notwithstanding Section 7.06, those Persons who were Holders at such record
date (or their duly designated proxies), and only those Persons, shall be entitled to give such consent or to revoke any consent
previously given or to take any such action, whether or not such Persons continue to be Holders after such record date. No such
consent shall be valid or effective for more than 90 days after such record date

 

SECTION 7.06.         Right
of Revocation of Action Taken. At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 7.01,
of the taking of any action by the Holders of the percentage in aggregate Principal Amount of the Securities of any series specified
in this Indenture in connection with such action, any Holder of a Security the serial number of which is shown by the evidence
to be included among the serial numbers of the Securities of the series the Holders of which have consented to such action may,
by filing written notice at the Corporate Trust Office and upon proof of holding as provided in this Article 7, revoke such action
so far as concerns such Security. Except as aforesaid, any such action taken by the Holder of any Security shall be conclusive
and binding upon such Holder and upon all future holders and owners of such Security and of any Securities issued in exchange
or substitution therefor, irrespective of whether or not any notation in regard thereto is made upon any such Security. Any action
taken by the Holders of the percentage in aggregate Principal Amount of the Securities of any series specified in this Indenture
in connection with such action shall be conclusively binding upon the Company, each Guarantor with respect to such series, if
any, the Trustee and the Holders of all the Securities of such series.

 

    	 	-28-	 

     

    

 

ARTICLE 8

MEETINGS OF HOLDERS

 

SECTION 8.01.         Purposes
for Which Meeting May Be Called. A meeting of Holders of Securities of any series may be called at any time and from time
to time pursuant to the provisions of this Article 8 for any of the following purposes:

 

(a)          to
give any notice to the Company, any Guarantor or to the Trustee, or to give any directions to the Trustee, or to consent to the
waiving of any Default or Event of Default with respect to the Securities of such series hereunder and its consequences, or take
any other action authorized to be taken by Holders of such series pursuant to any of the provisions of Article 5;

 

(b)          to
remove the Trustee and appoint a successor trustee with respect to the Securities of such series pursuant to the provisions of
Article 6;

 

(c)          to
consent to the execution of an indenture or indentures supplemental hereto pursuant to the provisions of Section 9.02; or

 

(d)          to
take any other action authorized to be taken by or on behalf of the Holders of the percentage in aggregate Principal Amount of
the Securities of such series under any other provisions of this Indenture or under applicable law.

 

SECTION 8.02.         Manner
of Calling Meetings; Record Date. The Trustee may at any time call a meeting of Holders of any series to take any action specified
in Section 8.01, to be held at such time and at such place in [●], or as the Trustee shall determine. Notice of every
meeting of Holders of any series setting forth the time and the place of such meeting and in general terms the action proposed
to be taken at such meeting, shall be mailed not less than 30 nor more than 60 calendar days prior to the date fixed for the meeting
to such Holders at their registered addresses. For the purpose of determining Holders entitled to notice of any meeting of Holders,
the Trustee shall fix in advance a date as the record date for such determination, such date to be a Business Day not more than
10 calendar days prior to the date of the mailing of such notice as hereinabove provided. Only persons in whose name a Security
of such series is registered upon the books of the Company on a record date fixed by the Trustee as aforesaid, or by the Company
or the Holders as in Section 8.03 provided, shall be entitled to notice of the meeting of Holders with respect to which such
record date was so fixed.

 

SECTION 8.03.         Call
of Meeting by Company or Holders. In case at any time the Company or a Guarantor, if any, pursuant to a resolution of its
Board of Directors, or the Holders of at least 10 percent in aggregate principal amount of the Securities of any series then outstanding,
shall have requested the Trustee to call a meeting of the Holders of such series to take any action authorized in Section 8.01
by written request setting forth in reasonable detail the action proposed to be taken at the meeting, and the Trustee shall not
have mailed notice of such meeting within 20 calendar days after receipt of such request, then the Company, any such Guarantor
or the Holders of Securities of such series in the amount above specified may fix the record date with respect to, and determine
the time and the place for, such meeting and may call such meeting to take any action authorized in Section 8.01, by mailing
notice thereof as provided in Section 8.02. The record date fixed as provided in the preceding sentence shall be set forth
in a written notice to the Trustee and shall be a Business Day not less than 15 nor more than 20 calendar days after the
date on which such notice is sent to the Trustee.

 

    	 	-29-	 

     

    

 

SECTION 8.04.         Who
May Attend and Vote at Meeting. To be entitled to vote at any meeting of Holders of any series, a person shall be a Holder
of one or more Securities of such series. The only persons who shall be entitled to be present or to speak at any meeting of Holders
of any series shall be the persons entitled to vote at such meeting and their counsel, any representatives of the Trustee and
its counsel, any representatives of the Company and its counsel, and any representatives of any Guarantor of such Securities and
its counsel. When a determination of Holders entitled to vote at any meeting of Holders has been made as provided in this Section 8.04,
such determination shall apply to any adjournment thereof.

 

SECTION 8.05.         Regulations.
Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable regulations as it may deem advisable
for any meeting of Holders of any series, in regard to proof of the holding of the Securities of such series and of the appointment
of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of proxies, certificates
and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit. Except
as otherwise permitted or required by any such regulations, the holding of the Securities of such series shall be provided in
the manner specified in Section 8.06.

 

The Trustee shall, by an instrument in writing,
appoint a temporary chairman of the meeting, unless the meeting shall have been called by the Company or by Holders as provided
in Section 8.03, in which case the Company or the Holders calling the meeting, as the case may be, shall in like manner appoint
a temporary chairman. A permanent chairman and a permanent secretary of the meeting shall be elected by a vote of the Holders of
a majority in Principal Amount of the Securities represented at the meeting and entitled to vote.

 

Subject to the provisions of Section 7.04,
at any meeting each Holder or proxy entitled to vote thereat shall be entitled to one vote for each $1,000 principal amount of
Securities of such series held or represented by him; provided that no vote shall be cast or counted at any meeting in respect
of any Security challenged as not outstanding and ruled by the chairman of the meeting to be not outstanding. The chairman of the
meeting shall have no right to vote other than by virtue of Securities held by him or instruments in writing as aforesaid duly
designating him as the person to vote on behalf of other Holders. Any meeting of Holders duly called pursuant to the provisions
of Section 8.02 or 8.03 may be adjourned from time to time, and the meeting may be held as so adjourned without further notice.

 

At any meeting of Holders of any series,
the presence of persons who held, or who are acting as proxy for persons who held, an aggregate Principal Amount of Securities
of such series on the record date for such meeting sufficient to take action on the business for the transaction of which such
meeting was called shall constitute a quorum, but, if less than a quorum is present, the persons holding or representing a majority
in aggregate Principal Amount of the Securities of such series represented at the meeting may adjourn such meeting with the same
effect, for all intents and purposes, as though a quorum had been present.

 

SECTION 8.06.         Manner
of Voting at Meetings and Record to be Kept. The vote upon any resolution submitted to any meeting of Holders of any series
shall be by written ballots on each of which shall be subscribed the signature of the Holder or proxy casting such ballot and
the identifying number or numbers of the Securities of such series held or represented in respect of which such ballot is cast.
The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for
or against any resolution and who shall make and file with the secretary of the meeting their verified written reports in duplicate
of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders shall be prepared by the
secretary of the meeting and there shall be attached to said record the original reports of the inspectors of votes on any vote
by ballot taken thereat and affidavits by one or more persons having knowledge of the facts setting forth a copy of the notice
of the meeting and showing that said notice was mailed as provided in Section 8.02. The record shall show the identifying
numbers of the Securities of such series voting in favor of or against any resolution. Each counterpart of such record shall be
signed and verified by the affidavits of the permanent chairman and secretary of the meeting and one of the counterparts shall
be delivered to the Company and the other to the Trustee to be preserved by the Trustee.

 

Any counterpart record so signed and verified
shall be conclusive evidence of the matters therein stated and shall be the record referred to in clause (b) of Section 7.01.

 

    	 	-30-	 

     

    

 

SECTION 8.07.         Exercise
of Rights of Trustee and Holders Not to be Hindered or Delayed. Nothing in this Article 8 contained shall be deemed or
construed to authorize or permit, by reason of any call of a meeting of Holders or any rights expressly or impliedly conferred
hereunder to make such call, any hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee
or to the Holders of any series under any of the provisions of this Indenture or of the Securities of such series.

 

ARTICLE 9

SUPPLEMENTAL INDENTURES

 

SECTION 9.01.         Supplemental
Indentures Without Consent of Holders. The Company, the Guarantors, if any, and the Trustee may amend or supplement this Indenture
or the Securities of any series or waive any provision hereof or thereof without the consent of any Holder:

 

(a)          to
cure any ambiguity, defect or inconsistency in a manner that does not, individually or in the aggregate with all other changes,
adversely affect the rights of any Holder of the Securities of any series in any material respect;

 

(b)          to
provide for uncertificated Securities in addition to or in place of certificated Securities;

 

(c)          to
evidence the assumption of the obligations of the Company or a Guarantor to the Holders of the Securities in the case of any transaction
pursuant to Article 10 hereof;

 

(d)          to
evidence and provide for the acceptance of appointment hereunder by a successor trustee and to add to or change any of the provisions
of the Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one
trustee;

 

(e)          to
make any change that would provide any additional rights or benefits to the Holders of all or any series of Securities or that
does not adversely affect the legal rights hereunder of any such Holder;

 

(f)          to
comply with requirements of the Commission in order to effect or maintain the qualification of this Indenture under the Trust Indenture
Act;

 

(g)          to
establish the form or terms of Securities of any series as permitted by Sections 2.01 and 3.01;

 

(h)          to
secure the Company’s obligations in respect of the Securities of any series;

 

(i)          to
add an additional Guarantor in respect of the Securities of any series.

 

(j)          in
the case of convertible or exchangeable Securities of any series, subject to the provisions of the supplemental indenture for such
series of Securities, to provide for conversion rights, exchange rights and/or repurchase rights of Holders of such series of Securities
in connection with any reclassification or change of the Company’s common stock or in the event of any amalgamation, consolidation,
merger or sale of all or substantially all of the assets of the Company or its Subsidiaries substantially as an entirety occurs;

 

(k)          in
the case of convertible or exchangeable Securities of any series, to reduce the conversion price or exchange price applicable to
such series of Securities;

 

(l)          in
the case of convertible or exchangeable Securities of any series, to increase the conversion rate or exchange ratio in the
manner described in the supplemental indenture for such series of Securities, provided that the increase will not
adversely affect the interests of the Holders of the Securities of such series in any material respect; or

 

(m)          any
other action to amend or supplement the Indenture or the Securities of any series as set forth in the supplemental indenture establishing
the terms of the Securities of that series as provided in Section 3.01(b).

 

    	 	-31-	 

     

    

 

Upon the request of the Company accompanied
by a resolution of its Board of Directors authorizing the execution of any such supplemental indenture, and upon receipt by the
Trustee of the documents described in Section 9.04 hereof, the Trustee shall join with the Company and the Guarantors, if
any, in the execution of any supplemental indenture authorized or permitted by the terms of this Indenture and to make any further
appropriate agreements and stipulations which may be therein contained, but the Trustee shall not be obligated to enter into such
supplemental indenture which affects its own rights, duties or immunities under this Indenture or otherwise.

 

SECTION 9.02.         With
Consent of Holders. Except as provided in the next succeeding paragraphs, this Indenture or the Securities may be amended
or supplemented with the consent of the Holders of at least a majority in aggregate Principal Amount of all the Securities then
outstanding affected by such supplemental indenture (acting as a single class).

 

Upon the request of the Company accompanied
by a resolution of its Board of Directors authorizing the execution of any such supplemental indenture, and upon the filing with
the Trustee of evidence satisfactory to the Trustee of the consent of the Holders as aforesaid, and upon receipt by the Trustee
of the documents described in Section 9.04 hereof, the Trustee shall join with the Company and the Guarantors, if any, in
the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, duties
or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to,
enter into such supplemental indenture.

 

It shall not be necessary for the consent
of the Holders under this Section 9.02 to approve the particular form of any proposed amendment or waiver, but it shall be
sufficient if such consent approves the substance thereof.

 

After an amendment, supplement or waiver
under this Section becomes effective, the Company shall mail to the Holders affected thereby a notice briefly describing the amendment,
supplement or waiver. Any failure of the Company to mail such notice, or any defect therein, shall not, however, in any way impair
or affect the validity of any such supplemental indenture or waiver. Subject to Sections 5.02(b), 5.04 and 5.07 hereof, the
application of or compliance with, either generally or in a particular instance, of any provision of this Indenture or the Securities
may be waived as to each series of Securities by the Holders of a majority in aggregate principal amount of the outstanding Securities
of that series.

 

Without the consent of each Holder affected
hereby, however, an amendment or waiver may not:

 

(a)          reduce
the percentage in Principal Amount of Securities of any series whose Holders must consent to an amendment, supplement or waiver;

 

(b)          change
the Stated Maturity of the principal of, or any installment of principal of or interest on, or time for payment of interest on,
any Security, or reduce the Principal Amount thereof or the rate of interest thereon or any premium payable upon the redemption
thereof, or change any Payment Office where, or the coin or currency in which, any Security or any premium or interest thereon
is payable, or impair the right to institute suit for the enforcement of any such payment on or after the Stated Maturity thereof
(or, in the case of redemption, on or after the redemption date);

 

(c)          modify
any of the provisions of this Section 9.02, Section 5.04 or Section 4.06, except to increase the percentage in Principal
Amount of Holders required under any such Section or to provide that certain other provisions of this Indenture cannot be modified
or waived without the consent of the Holder of each outstanding Security affected thereby, provided that this clause (c) will
not be deemed to require the consent of any Holder with respect to changes in the references to “the Trustee” and concomitant
changes in this Section 9.02, Section 5.02(b), Section 5.04 and Section 4.06, or the deletion of this proviso, in accordance
with the requirements of Section 6.11;

 

(d)          impair
the rights of Holders of the Securities of any series that are exchangeable or convertible to receive payment or delivery of any
consideration due upon the conversion or exchange of the Securities of that series;

 

    	 	-32-	 

     

    

 

(e)          change
in any manner adverse to the interests of the Holders of any outstanding Securities the terms and conditions of the obligations
of the Guarantors, if applicable, in respect of the due and punctual payment of the principal thereof (and premium, if any, thereon)
and interest thereon or any additional amounts or any sinking fund or analogous payments provided in respect thereof; or

 

(f)          modify
or amend any of the provisions of the Indenture or Securities of any series as may be set forth in the supplemental indenture with
respect to the Securities of that series as requiring the consent of each Holder affected thereby.

 

SECTION 9.03.         Effect
of Supplemental Indenture. Upon the execution of any supplemental indenture pursuant to the provisions hereof, this Indenture
shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations,
duties and immunities under this Indenture of the Trustee, the Company, each Guarantor, if any, and the Holders shall thereafter
be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms
and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture
for any and all purposes.

 

SECTION 9.04.         Documents
to Be Given to Trustee; Compliance with TIA. The Trustee, subject to the provisions of Sections 6.01 and 6.02, shall
be entitled to receive and conclusively rely upon an Officers’ Certificate and an Opinion of Counsel as conclusive evidence
that any such supplemental indenture is permitted or authorized under and otherwise complies with the applicable provisions of
this Indenture. Every such supplemental indenture shall comply with the TIA.

 

SECTION 9.05.         Notation
on Securities in Respect of Supplemental Indentures. Securities authenticated and delivered after the execution of any supplemental
indenture pursuant to the provisions of this Article may bear a notation approved by the Trustee as to form (but not as to substance)
as to any matter provided for by such supplemental indenture or as to any action taken at any such meeting. If the Company, any
applicable Guarantor or the Trustee shall so determine, new Securities of any series so modified as to conform, in the opinion
of the Trustee and the Board of Directors of the Company, to any modification of this Indenture contained in any such supplemental
indenture may be prepared by the Company, endorsed by any such Guarantor, authenticated by the Trustee and delivered in exchange
for the Securities of such series then outstanding.

 

ARTICLE 10

CONSOLIDATION, MERGER OR SALE OF ASSETS

 

SECTION 10.01.         When
the Company May Merge, Etc. The Company shall not consolidate with or merge with or into, or sell, transfer, lease, convey
or otherwise dispose of all or substantially all of its assets to, another Person (including pursuant to a statutory arrangement),
whether in a single transaction or series of related transactions, unless:

 

(a)          the
Company is the surviving entity or the Person formed by or surviving any such consolidation or merger or to which such sale, transfer,
lease, conveyance or other disposition is made shall be a Person organized and existing under the laws of the United States of
America or any State or the District of Columbia, and shall expressly assume, by an indenture supplemental hereto, executed and
delivered to the Trustee, the due and punctual payment of the principal of (and premium, if any) and interest, if any, on all the
Securities and the performance or observance of every covenant of this Indenture of the part of the Company to be performed or
observed;

 

(b)          immediately
after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time, or both, would
become an Event of Default, shall have happened and be continuing; and

 

(c)          the
Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel each stating that such consolidation,
merger, conveyance or transfer and, if a supplemental indenture is required in connection with such transaction, such supplemental
indenture comply with this Article and that all conditions precedent herein provided for relating to such transaction have been
complied with.

 

    	 	-33-	 

     

    

 

SECTION 10.02.         Successor
Person Substituted. Upon any consolidation or merger, or any sale, transfer, lease, conveyance or other disposition of all
or substantially all of the assets of the Company in accordance with Section 10.01 hereof, the successor Person formed by
such consolidation or into or with which the Company is merged or to which such sale, transfer, lease, conveyance or other disposition
is made shall succeed to, and, except in the case of a lease, be substituted for (so that from and after the date of such consolidation,
merger, sale, transfer, conveyance or other disposition, the provisions of this Indenture referring to the “Company”
shall refer instead to the successor Person), and may exercise every right and power of, the Company under this Indenture with
the same effect as if such successor Person had been named as the Company herein.

 

In case of any such consolidation, merger,
sale, transfer, lease, conveyance or other disposition such changes in phraseology and form (but not in substance) may be made
in the Securities thereafter to be issued as may be appropriate. Notwithstanding the foregoing, (i) a consolidation or merger
by the Company with or into, or (ii) the sale, transfer, lease, conveyance or other disposition by the Company of all or substantially
all of its assets to, one or more of its Subsidiaries shall not relieve the Company from its obligations under this Indenture and
the Securities.

 

SECTION 10.03.         Opinion
of Counsel to Trustee. The Trustee, subject to the provisions of Sections 6.01 and 6.02, may receive an Opinion of Counsel
as conclusive evidence that any such consolidation, merger, sale, transfer, lease, conveyance or other disposition complies with
the applicable provisions of this Indenture.

 

ARTICLE 11

REDEMPTION OF SECURITIES

 

SECTION 11.01.         Applicability
of Article. Securities of any series which are redeemable before their Stated Maturity shall be redeemable in accordance with
their terms and (except as otherwise specified as contemplated by Section 3.01 for Securities of any series) in accordance
with this Article.

 

SECTION 11.02.         Notice
of Redemption; Partial Redemptions. Notice of redemption to the Holders of Securities of any series to be redeemed as a whole
or in part shall be given by mailing notice of such redemption by first class mail, postage prepaid, at least 30 calendar
days and not more than 60 calendar days prior to the date fixed for redemption to such Holders of Securities at their last
addresses as they shall appear upon the registry books. Any notice which is mailed in the manner herein provided shall be conclusively
presumed to have been duly given, whether or not the Holder receives the notice. Failure to give notice by mail, or any defect
in the notice to the Holder of any Security designated for redemption as a whole or in part shall not affect the validity of the
proceedings for the redemption of any other Security.

 

The notice of redemption to each such Holder
shall identify the Securities to be redeemed (including CUSIP numbers) and shall specify the Principal Amount of each Security
held by such Holder to be redeemed, the date fixed for redemption, the redemption price, the place or places of payment, that payment
will be made upon presentation and surrender of such Securities, that interest accrued to the date fixed for redemption will be
paid as specified in said notice and that on and after said date interest thereon or on the portions thereof to be redeemed will
cease to accrue. In case any Security is to be redeemed in part only the notice of redemption shall state the portion of the Principal
Amount thereof to be redeemed and shall state that on and after the date fixed for redemption, upon surrender of such Security,
a new Security or Securities in Principal Amount equal to the unredeemed portion thereof will be issued.

 

The notice of redemption of Securities of
any series to be redeemed at the option of the Company shall be given by the Company or, at the Company’s request, by the
Trustee in the name and at the expense of the Company.

 

No later than 10:00 a.m. New York City
time on the redemption date specified in the notice of redemption given as provided in this Section, the Company will deposit with
the Trustee or with one or more Paying Agents (or, if the Company is acting as its own Paying Agent, set aside, segregate and hold
in trust) an amount of money sufficient to redeem on the redemption date all the Securities of a series so called for redemption
at the appropriate redemption price, together with accrued interest to the date fixed for redemption. The Company will deliver
to the Trustee at least 30 calendar days prior to the date fixed for redemption an Officers’ Certificate stating the
aggregate Principal Amount of Securities of such series to be redeemed.

 

    	 	-34-	 

     

    

 

If less than all the Securities of a series
are to be redeemed, the Trustee shall select, either pro rata, by lot or by any other method it shall deem fair and reasonable,
Securities to be redeemed in whole or in part. Securities may be redeemed in part only in denominations equal to the minimum authorized
denomination for Securities of that series or any integral multiple thereof. The Trustee shall promptly notify the Company in writing
of the Securities selected for redemption and, in the case of any Securities selected for partial redemption, the Principal Amount
thereof to be redeemed. For all purposes of this Indenture, unless the context otherwise requires, all provisions relating to the
redemption of Securities shall relate, in the case of any Security redeemed or to be redeemed only in part, to the portion of the
Principal Amount of such Security which has been or is to be redeemed.

 

SECTION
11.03.         Payment of Securities Called for Redemption. If notice of
redemption has been given as above provided, the Securities or portions of Securities specified in such notice shall become
due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest
accrued to, but not including, the date fixed for redemption, and on and after said date (unless the Company and any
Guarantors shall default in the payment of such Securities at the redemption price, together with interest accrued to said
date) interest on the Securities or portions of Securities so called for redemption shall cease to accrue and, except as
provided in Sections 6.05 and 12.06, such Securities shall cease from and after the date fixed for redemption to be
entitled to any benefit or security under this Indenture, and the Holders thereof shall have no right in respect of such
Securities except the right to receive the redemption price thereof and unpaid interest to the date fixed for redemption. On
presentation and surrender of such Securities at a Payment Office specified in said notice, said Securities or the
specified portions thereof shall be paid and redeemed by the Company at the applicable redemption price, together with
interest accrued thereon to, but not including, the date fixed for redemption; provided that any payment of interest
becoming due on the date fixed for redemption shall be payable to the Holders of such Securities registered as such on the
relevant Regular Record Date subject to the terms and provisions of Section 3.05 hereof.

 

If any Security called for redemption shall
not be so paid upon surrender thereof for redemption, the principal shall, until paid or duly provided for, bear interest from
the date fixed for redemption at the rate borne by the Security.

 

Upon presentation of any Securities redeemed
in part only, the Company shall execute, the Guarantors, if any, shall, execute the Guarantees endorsed thereon, and the Trustee
shall authenticate and make available for delivery to or on the order of the Holder thereof, at the expense of the Company, new
Securities of authorized denominations, in Principal Amount equal to the unredeemed portion of the Securities so presented.

 

ARTICLE 12

DEFEASANCE AND COVENANT DEFEASANCE

 

SECTION 12.01.         Applicability
of the Article; Company’s Option to Effect Defeasance or Covenant Defeasance. Unless pursuant to Section 3.01 provision
is made for the inapplicability of either or both of (a) defeasance of the Securities of a series under Section 12.02
or (b) covenant defeasance of the Securities of a series under Section 12.03, then the provisions of such Section or Sections,
as the case may be, together with the other provisions of this Article, shall be applicable to the Securities of such series,
and the Company may, at its option, by resolution of its Board of Directors, at any time, elect to have either Section 12.02
or Section 12.03 applied to the outstanding Securities of a series upon compliance with the conditions set forth below in
this Article 12.

 

    	 	-35-	 

     

    

 

SECTION 12.02.         Legal
Defeasance and Discharge. Upon the Company’s exercise of the option provided under Section 12.01 hereof to defease
the outstanding Securities of a particular series under this Section 12.02, the Company and any Guarantors shall be deemed
to have been discharged from its obligations with respect to such outstanding Securities and related Guarantees on the date the
conditions set forth below are satisfied (hereinafter, “Legal Defeasance”). For this purpose, such Legal Defeasance
means that the Company shall be deemed to have paid and discharged the entire indebtedness represented by the outstanding Securities
of such series, which shall thereafter be deemed to be “outstanding” only for the purposes of Section 12.05 hereof
and the other Sections of this Indenture referred to in clauses (i) and (ii) of this Section 12.02, and to have
satisfied all its other obligations under such Securities and this Indenture (and the Trustee, on demand of and at the expense
of the Company shall execute proper instruments acknowledging the same), except for the following provisions which shall survive
until otherwise terminated or discharged hereunder: (i) the rights of Holders of outstanding Securities of such series to
receive solely from the trust fund described in Section 12.04 hereof, and as more fully set forth in such Section, payments
in respect of the principal of (and premium, if any) and interest, if any, on such Securities when such payments are due, (ii) the
obligations of the Company or any Guarantor with respect to such Securities under Sections 3.06, 3.07, 3.08(a), 3.09, 3.11,
and 12.05 hereof, (iii) the rights, powers, trusts, duties and immunities of the Trustee hereunder, including, without limitation,
the Trustee’s rights under Section 6.07 hereof, and the obligations of the Company or any Guarantor in connection therewith
and with this Article 12. Subject to compliance with this Article 12, the Company may exercise its option under this
Section 12.02 notwithstanding the prior exercise of its option under Section 12.03 hereof with respect to the Securities
of such series.

 

SECTION 12.03.         Covenant
Defeasance. Upon the Company’s exercise of the option provided under Section 12.01 hereof to obtain a covenant
defeasance with respect to the outstanding Securities of a particular series under this Section 12.03, the Company and any
Guarantors shall be released from their obligations under the covenants contained in Article 4 and Section 10.01 hereof
and the covenants contained in any supplemental indenture applicable to such series, with respect to the outstanding Securities
of such series on and after the date the conditions set forth below are satisfied (hereinafter, “Covenant Defeasance”),
and the Securities of such series shall thereafter be deemed not outstanding for the purposes of any direction, waiver, consent
or declaration or act of Holders (and the consequences of any thereof) in connection with such covenants, but shall continue to
be deemed outstanding for all other purposes hereunder. For this purpose, such Covenant Defeasance means that, with respect to
the outstanding Securities of such series, the Company or any Guarantors may omit to comply with and shall have no liability in
respect of any term, condition or limitation set forth in any such covenant, whether directly or indirectly, by reason of any
reference elsewhere herein to any such covenant or by reason of any reference in any such covenant to any other provision herein
or in any other document and such omission to comply shall not constitute a Default or an Event of Default under Section 5.01(c)
or Section 5.01(g) with respect to outstanding Securities of such series, but, except as specified above, the remainder of this
Indenture and of the Securities of such series shall be unaffected thereby.

 

SECTION 12.04.         Conditions
to Legal or Covenant Defeasance. The following shall be the conditions to the application of either Section 12.02 or
Section 12.03 hereof to the outstanding Securities of a particular series:

 

(a)          The
Company shall irrevocably have deposited or caused to be deposited with the Trustee (or another trustee satisfying the requirements
of Section 6.09 who shall agree to comply with the provisions of this Article 12 applicable to it) as trust funds in
trust for the purpose of making the following payments, specifically pledged as security for, and dedicated solely to, the benefit
of the Holders of such Securities, (i) an amount (in such currency, currencies or currency unit in which such Securities and
any related coupons are then specified as payable at Stated Maturity), or (ii) non-callable Government Securities that through
the scheduled payment of principal and interest in respect thereof in accordance with their terms will provide, not later than
one day before the due date of any payment, cash in Dollars in an amount, or (iii) a combination thereof, in such amounts
as will be sufficient, in the opinion of a nationally recognized firm of independent public accountants expressed in a written
certification thereof delivered to the Trustee, to pay and discharge and which shall be applied by the Trustee (or other qualifying
trustee) to pay and discharge the principal of (and premium, if any) and interest, if any, on such outstanding Securities on the
stated maturity date of such principal or installment of principal, or interest or premium, if any.

 

(b)          In
the case of an election under Section 12.02 hereof, the Company shall have delivered to the Trustee an Opinion of Counsel
confirming that (i) the Company has received from, or there has been published by, the Internal Revenue Service a ruling or
(ii) since the date hereof, there has been a change in the applicable federal income tax law, in either case to the effect
that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the outstanding Securities of such series will
not recognize income, gain or loss for federal income tax purposes as a result of such Legal Defeasance and will be subject to
federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such Legal Defeasance
had not occurred.

 

    	 	-36-	 

     

    

 

(c)          In
the case of an election under Section 12.03 hereof, the Company shall have delivered to the Trustee an Opinion of Counsel
confirming that the Holders of the outstanding Securities of such series will not recognize income, gain or loss for federal income
tax purposes as a result of such Covenant Defeasance and will be subject to federal income tax on the same amounts, in the same
manner and at the same times as would have been the case if such Covenant Defeasance had not occurred.

 

(d)          No
Default or Event of Default (or event that, with the giving of notice or lapse of time or both would become an Event of Default)
with respect to the Securities of such series shall have occurred and be continuing on the date of such deposit or, insofar as
Section 5.01(d) or 5.01(e) hereof is concerned, at any time in the period ending on the 124th calendar day after the date
of such deposit (it being understood that this condition shall not be deemed satisfied until the expiration of such period).

 

(e)          Such
Legal Defeasance or Covenant Defeasance shall not result in a breach or violation of, or constitute a default under any material
agreement or instrument (other than this Indenture) to which the Company or any Guarantor is a party or by which the Company or
such Guarantor is bound (other than a breach, violation or default resulting from the borrowing of funds to be applied to such
deposit).

 

(f)          The
Company shall have delivered to the Trustee an Officers’ Certificate stating that the deposit made by the Company pursuant
to its election under Section 12.02 or 12.03 hereof was not made by the Company with the intent of preferring the Holders
of the affected Securities over the other creditors of the Company with the intent of defeating, hindering, delaying or defrauding
creditors of the Company, or others.

 

(g)          Such
Legal Defeasance or Covenant Defeasance shall be effected in compliance with any additional terms, conditions or limitations which
may be imposed on the Company in connection therewith pursuant to Section 3.01.

 

(h)          The
Company shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions
precedent provided for relating to either the Legal Defeasance under Section 12.02 hereof or the Covenant Defeasance under
Section 12.03 hereof (as the case may be) have been complied with as contemplated by this Section 12.04.

 

SECTION 12.05.         Deposited
Money and Government Securities to be Held in Trust; Other Miscellaneous Provisions. Subject to Section 12.06 hereof,
all money and non-callable Government Securities (including the proceeds thereof) deposited with the Trustee pursuant to Section 12.04
hereof in respect of the outstanding Securities of a particular series shall be held in trust and applied by the Trustee, in accordance
with the provisions of such Securities, the Guarantees, if any, relating to such series of Securities and this Indenture, to the
payment, either directly or through any Paying Agent (including the Company acting as Paying Agent) as the Trustee may determine,
to the Holders of such Securities of all sums due and to become due thereon in respect of principal (and premium, if any) and
interest, if any, but such money need not be segregated from other funds except to the extent required by law.

 

The Company shall pay and indemnify the
Trustee against any tax, fee or other charge imposed on or assessed against the cash or non-callable Government Securities deposited
pursuant to Section 12.04 hereof or the principal and interest received in respect thereof other than any such tax, fee or other
charge that by law is for the account of the Holders of the outstanding Securities of such series.

 

Anything in this Article 12 to the
contrary notwithstanding, the Trustee shall deliver or pay to the Company from time to time upon the Company’s request any
money or non-callable Government Securities held by it as provided in Section 12.04 hereof with respect to the Securities
of any series which, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification
thereof delivered to the Trustee (which may be the opinion delivered under Section 12.04(a) hereof), are in excess of the
amount thereof which would then be required to be deposited to effect an equivalent Legal Defeasance or Covenant Defeasance.

 

    	 	-37-	 

     

    

 

SECTION 12.06.         Repayment
to the Company or Guarantor. Any money deposited with the Trustee or any Paying Agent, or then held by the Company or applicable
Guarantor, in trust for the payment of the principal of (and premium, if any) and interest, if any, on any Security and remaining
unclaimed for two years after such principal, or interest or premium, if any, has become due and payable and was deposited with
the Paying Agent shall be paid to the Company or such Guarantor on its written request (or if then held by the Company or such
Guarantor) will be discharged from such trust) subject to any applicable abandoned property law; and the Holder of such Security
shall thereafter, as an unsecured general creditor, look only to the Company or such Guarantor for payment thereof, and all liability
of the Trustee or such Paying Agent with respect to such trust money, and all liability of the Company or such Guarantor as trustee
thereof, shall thereupon cease.

 

SECTION 12.07.         Reinstatement.
If the Trustee or Paying Agent is unable to apply any Dollars or non-callable Government Securities in accordance with Section 12.02
or 12.03 hereof, as the case may be, by reason of any order or judgment of any court or governmental authority enjoining, restraining
or otherwise prohibiting such application, then the obligations of the Company and the applicable Guarantors under this Indenture,
the Securities and any Guarantees shall be revived and reinstated as though no deposit had occurred pursuant to Section 12.02
or 12.03 hereof until such time as the Trustee or Paying Agent is permitted to apply all such money in accordance with Section 12.02
or 12.03 hereof, as the case may be; provided that, if the Company or any Guarantor makes any payment of principal of,
or interest or premium, if any, on any Security following the reinstatement of its obligations, the Company or any Guarantor shall
be subrogated to the rights of the Holders of such Security to receive such payment from the money held by the Trustee or Paying
Agent.

 

ARTICLE 13

SATISFACTION AND DISCHARGE

 

SECTION 13.01.         Satisfaction
and Discharge of Indenture. This Indenture shall upon a Company Request cease to be of further effect with respect to any
series of Securities (except, as to any surviving rights of registration of transfer, exchange or conversion of Securities of
such series herein expressly provided for or in the form of Security for such series and any rights to receive payment of interest
thereon), and the Trustee, on demand of and at the expense of the Company, shall execute proper instruments acknowledging satisfaction
and discharge of this Indenture, when:

 

(a)          either

 

(i)          all
Securities of such series theretofore authenticated and delivered (other than (A) Securities which have been destroyed, lost
or stolen and which have been replaced or paid as provided in Section 3.09, and (B) Securities for whose payment money
has theretofore been (x) deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company
or discharged from such trust, as provided in Section 4.03(c) or (y) paid to any State or the District of Columbia pursuant
to its unclaimed property or similar laws) have been delivered to the Trustee for cancellation; or

 

(ii)         all
such Securities not theretofore delivered to the Trustee for cancellation

 

(A)         have
become due and payable (whether at Stated Maturity, upon redemption (if applicable), upon any required repurchase by the Company
(if applicable) or otherwise), or

 

(B)         will
become due and payable at their stated maturity within one year, or

 

(C)         are
to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption
by the Trustee in the name, and at the expense, of the Company, and the Company, in the case of (A), (B) or (C) above,
has deposited or caused to be deposited with the Trustee, as trust funds in trust for the purpose, money in the amount in the currency
or currency units in which the Securities of such series are payable, sufficient to pay and discharge the entire indebtedness on
such Securities not theretofore delivered to the Trustee for cancellation, for principal (and premium, if any) and interest, if
any, to the date of such deposit (in the case of Securities which have become due and payable), or to the Stated Maturity or redemption
date, as the case may be;

 

    	 	-38-	 

     

    

 

(b)          the
Company or a Guarantor, if any, has paid or caused to be paid all other sums payable hereunder by the Company or the Guarantors,
if any; and

 

(c)          the
Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel each stating that all conditions
precedent herein provided for relating to the satisfaction and discharge of this Indenture have been complied with.

 

Notwithstanding the satisfaction and discharge
of this Indenture, the obligations of the Company to the Trustee under Section 6.07 and, if money shall have been deposited
with the Trustee pursuant to subclause (ii) of clause (a) of this Section, the obligations of the Trustee under Section 13.02
and Section 4.03(e) shall survive.

 

SECTION 13.02.         Application
of Trust Money. Subject to the provisions of Section 4.03(e), all money deposited with the Trustee pursuant to Section 13.01
shall be held in trust and applied by it, in accordance with the provisions of the Securities, the Guarantees, if any, relating
to such series of Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company
acting as its own Paying Agent), as the Trustee may determine, to the Persons entitled thereto, of the principal (and premium,
if any) and interest, if any, for whose payment such money has been deposited with the Trustee.

 

ARTICLE 14

HOLDERS’ LISTS AND REPORTS BY TRUSTEE, COMPANY AND GUARANTORS

 

SECTION 14.01.         Company
to Furnish Trustee Names and Addresses of Holders. The Company will furnish or cause to be furnished to the Trustee:

 

(a)          semi-annually,
not later than 15 calendar days after the Regular Record Date for each series of Securities, a list, in such form as the Trustee
may reasonably require, of the names and addresses of the Holders of Securities as of such Regular Record Date (unless the Trustee
has such information), or if there is no Regular Record Date for interest for such series of Securities, semi-annually, upon such
dates as are set forth in the Board Resolution of the Company or indenture supplemental hereto authorizing such series, and

 

(b)          at
such other times as the Trustee may request in writing, within 30 calendar days after the receipt by the Company of any such
request, a list of similar form and content as of a date not more than 15 calendar days prior to the time such list is furnished;

 

provided that so long as the Trustee is the Registrar,
no such list shall be required to be furnished.

 

SECTION 14.02.         Preservation
of Information; Communications to Holders.

 

(a)          The
Trustee shall preserve, in as current a form as is reasonably practicable, the names and addresses of Holders contained in the
most recent list furnished to the Trustee as provided in Section 14.01 and the names and addresses of Holders received by
the Trustee in its capacity as the Registrar. The Trustee may destroy any list furnished to it as provided in Section 14.01
upon receipt of a new list so furnished.

 

(b)          If
three or more Holders (herein referred to as “applicants”) apply in writing to the Trustee, and furnish to the Trustee
reasonable proof that each such applicant has owned a Security for a period of at least six months preceding the date of such application
(or since the first date of the issuance for such Security, if the holding period is less than six months), and such application
states that the applicants desire to communicate with other Holders with respect to their rights under this Indenture or under
the Securities and is accompanied by a copy of the form of proxy or other communication which such applicants propose to transmit,
then the Trustee shall, within five Business Days after the receipt of such application, at its election, either

 

    	 	-39-	 

     

    

 

(i)          afford
such applicants access to the information preserved at the time by the Trustee in accordance with Section 14.02(a); or

 

(ii)         inform
such applicants as to the approximate number of Holders whose names and addresses appear in the information preserved at the time
by the Trustee in accordance with Section 14.02(a), and as to the approximate cost of mailing to such Holders the form of
proxy or other communication, if any, specified in such application.

 

If the Trustee shall elect not to afford
such applicants access to such information, the Trustee shall, upon the written request of such applicants, mail to each Holder
whose name and address appears in the information preserved at the time by the Trustee in accordance with Section 14.02(a) a copy
of the form of proxy or other communication which is specified in such request, with reasonable promptness after a tender to the
Trustee of the material to be mailed and of payment, or provision for the payment, of the reasonable expenses of mailing, unless
within five Business Days after such tender the Trustee shall mail to such applicants and file with the Commission, together with
a copy of the material to be mailed, a written statement to the effect that, in the opinion of the Trustee, such mailing would
be contrary to the best interest of the Holders or would be in violation of applicable law. Such written statement shall specify
the basis of such opinion. If the Commission, after opportunity for a hearing upon the objections specified in the written statement
so filed, shall enter an order refusing to sustain any of such objections or if, after the entry of an order sustaining one or
more of such objections, the Commission shall find, after notice and opportunity for hearing, that all objections so sustained
have been met and shall enter an order so declaring, the Trustee shall mail copies of such material to all such Holders with reasonable
promptness after the entry of such order and the renewal of such tender; otherwise the Trustee shall be relieved of any obligation
or duty to such applicants respecting their application.

 

(c)          Every
Holder of Securities, by receiving and holding the same, agrees with the Company, any applicable Guarantor and the Trustee that
none of the Company, such Guarantors and the Trustee nor any of their respective agents shall be held accountable by reason of
the disclosure of any such information as to the names and addresses of the Holders in accordance with Section 14.02(b), regardless
of the source from which such information was derived, and that the Trustee shall not be held accountable by reason of mailing
any material pursuant to a request made under Section 14.02(b).

 

SECTION 14.03.         Reports
by the Trustee.

 

(a)          The
Trustee shall transmit to Holders such reports concerning the Trustee and its actions under this Indenture as may be required pursuant
to the Trust Indenture Act at the times and in the manner provided pursuant thereto. If required by Section 313(a) of the Trust
Indenture Act, the Trustee shall, within 60 calendar days after each May 15th following the date of this Indenture (commencing
May 15, [●]) deliver to Holders a brief report, dated as of such May 15th, which complies with the provisions of
such Section 313(a).

 

(b)          A
copy of each such report shall, at the time of such transmission to Holders, be filed by the Trustee with each securities exchange
upon which Securities of any series are listed, with the Commission and with the Company. The Company will promptly notify the
Trustee when any Securities are listed on any securities exchange and of any delisting thereof.

 

SECTION
14.04.         Reports by the Company and Guarantors. The Company
shall furnish to the Trustee, within 15 calendar days after it actually files such annual and quarterly reports,
information, documents and other reports with the Commission, copies of its annual report and of the information, documents
and other reports (or copies of such portions of any of the foregoing the Commission may by rules and regulations prescribe)
that the Company is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act; provided
that any such annual and quarterly reports, information, documents and other reports and information filed with the
Commission may be provided by the Company to the Trustee electronically. The Company and any Guarantor shall comply with the
other provisions of TIA Section 314(a). Delivery of such information, documents and reports to the Trustee is
for informational purposes only and the Trustee’s receipt of such shall not constitute constructive notice of
any information contained therein or determinable from information contained therein, including the Company’s
compliance with any of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on
Officers’ Certificates). It is expressly understood that materials transmitted electronically by the Company to the
Trustee or filed pursuant to the Commission’s EDGAR system (or any successor electronic filing system) shall be deemed
filed with the Trustee and transmitted to Holders for purposes of this Section 14.04.

 

    	 	-40-	 

     

    

 

ARTICLE 15

MISCELLANEOUS PROVISIONS

 

SECTION 15.01.         Incorporators,
Stockholders, Members, Partners, Officers, Managers and Directors of Company or any Guarantor Exempt from Individual Liability.
No recourse under or upon any obligation, covenant or agreement contained in this Indenture, or in any Security of any series
or any Guarantees, or because of any indebtedness evidenced thereby, shall be had against any incorporator, as such or against
any past, present or future stockholder, member, partner, officer, manager or director, as such, of the Company, any Guarantor
or any successor, either directly or through the Company, any Guarantor or any successor, under any rule of law, statute or constitutional
provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise, all such liability being
expressly waived and released by the acceptance of the Securities of such series by the Holders thereof and as part of the consideration
for the issue of the Securities of such series.

 

SECTION 15.02.         Provisions
of Indenture for the Sole Benefit of Parties and Holders. Except as set forth in Section 15.10, nothing in this Indenture
or in the Securities of any series, expressed or implied, shall give or be construed to give to any person, firm or corporation,
other than the parties hereto and their successors and the Holders of the Securities of such series, any legal or equitable right,
remedy or claim under this Indenture or under any covenant or provision herein contained, all such covenants and provisions being
for the sole benefit of the parties hereto and their successors and of the Holders of the Securities.

 

SECTION 15.03.         Successors
and Assigns of Company or Guarantor Bound by Indenture. All the covenants, stipulations, promises and agreements in this Indenture
contained by or in behalf of the Company or any Guarantor shall bind their successors and assigns, whether so expressed or not.

 

SECTION 15.04.         Notices,
Etc., to Trustee, the Company and Guarantors. Any request, demand, authorization, direction, notice, consent, waiver or act
of Holders or other document provided or permitted by this Indenture to be made upon, given or furnished to, or filed with:

 

(1)          the
Trustee by any Holder, or by the Company or a Guarantor, if any, shall be sufficient for every purpose hereunder if made,
given, furnished or filed in writing to or with the Trustee at [●], facsimile [●], or such other facsimile number
as may be provided by the Trustee from time to time, and shall be deemed to have been made at the time of actual receipt of
such written notice or facsimile transmission thereof; provided that any delivery made or facsimile sent on a day
other than a Business Day shall be deemed to be received on the next following Business Day; or

 

(2)          the
Company or a Guarantor, if any, by the Trustee or by any Holder shall be sufficient for every purpose hereunder (unless
otherwise herein expressly provided) if in writing to the Company or such Guarantor, as the case may be, addressed to it at
the address specified in Schedule I hereto or at any other address or facsimile number previously furnished in writing to the
Trustee by the Company or such Guarantor, as the case may be, and shall be deemed to have been made at the time of delivery
or facsimile transmission; provided that any delivery made or facsimile sent on a day other than a Business Day shall
be deemed to be received on the next following Business Day.

 

SECTION 15.05.       Notices
to Holders. Where this Indenture provides for notice to Holders, such notice shall be sufficiently given (unless otherwise
herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder entitled thereto, at its last
address as it appears in the Security Register. In any case where notice to Holders is given by mail, neither the failure to mail
such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with
respect to other Holders. Where this Indenture provides for notice in any manner, such notice may be waived in writing by the
person entitled to receive such notice, either before or after the event, and such waiver shall be the equivalent of such notice.
The Trustee may waive notice to it of any provision herein, and such waiver shall be deemed to be for its convenience and discretion.
Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity
of any action taken in reliance upon such waiver.

 

    	 	-41-	 

     

    

 

In case, by reason of the suspension of
or irregularities in regular mail service, it shall be impracticable to mail notice to the Company, any Guarantor or any Holders
when such notice is required to be given pursuant to any provision of this Indenture, then any manner of giving such notice as
shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice.

 

SECTION 15.06.         Officers’
Certificates and Opinions of Counsel; Statements to Be Contained Therein. Upon any application or demand by the Company or
any Guarantor to the Trustee to take any action under any of the provisions of this Indenture, the Company or such Guarantor,
as the case may be, shall furnish to the Trustee an Officers’ Certificate stating that all conditions precedent provided
for in this Indenture relating to the proposed action have been complied with and an Opinion of Counsel stating that in the opinion
of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand
as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular
application or demand, no additional certificate or opinion need be furnished.

 

Each certificate or opinion provided for
in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant provided for in this Indenture
shall include (a) a statement that the person making such certificate or opinion has read such covenant or condition, (b) a
brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained
in such certificate or opinion are based, (c) a statement that, in the opinion of such person, he has made such examination
or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has
been complied with and (d) a statement as to whether or not, in the opinion of such person, such condition or covenant has
been complied with.

 

Any certificate, statement or opinion of
an officer of the Company or any Guarantor may be based, insofar as it relates to legal matters, upon a certificate or opinion
of or representations by counsel, unless such officer knows that the certificate or opinion or representations with respect to
the matters upon which his or her certificate, statement or opinion may be based as aforesaid are erroneous, or in the exercise
of reasonable care should know that the same are erroneous. Any certificate, statement or Opinion of Counsel may be based, insofar
as it relates to factual matters or information which is in the possession of the Company, upon the certificate, statement or opinion
of or representations by an officer or officers of the Company or such Guarantor, as the case may be, unless such counsel knows
that the certificate, statement or opinion or representations with respect to the matters upon which his or her certificate, statement
or opinion may be based as aforesaid are erroneous, or in the exercise of reasonable care should know that the same are erroneous.

 

Any certificate, statement or opinion of
an officer or counsel of the Company or any Guarantor may be based, insofar as it relates to accounting matters, upon a certificate
or opinion of or representations by an accountant or firm of accountants in the employ of the Company or such Guarantor, as the
case may be, unless such officer or counsel knows that the certificate or opinion or representations with respect to the accounting
matters upon which his or her certificate, statement or opinion may be based as aforesaid are erroneous, or in the exercise of
reasonable care should know that the same are erroneous.

 

Any certificate or opinion of any independent
firm of public accountants filed with the Trustee shall contain a statement that such firm is independent within the meaning of
the Securities Act and the rules and regulations promulgated thereunder.

 

SECTION 15.07.         Payments
Due on Saturdays, Sundays and Holidays. If the Stated Maturity of interest on or principal of the Securities of a particular
series or the date fixed for redemption of any Security shall not be a Business Day, then payment of interest or principal with
respect to such Securities need not be made on such date, but may be made on the next succeeding Business Day with the same force
and effect as if made on the date of maturity or the date fixed for redemption, and no interest shall accrue for the period after
such date.

 

    	 	-42-	 

     

    

 

SECTION 15.08.         Conflict
of Any Provision of Indenture with Trust Indenture Act. If and to the extent that any provision of this Indenture limits,
qualifies or conflicts with another provision included in this Indenture by operation of Sections 310 to 317, inclusive,
of the Trust Indenture Act (an “incorporated provision”), such incorporated provision shall control.

 

SECTION 15.09.         Conflict
of Any Provision of Securities with Indenture. If and to the extent that any provision of the Securities limits, qualifies
or conflicts with a provision of this Indenture, such provision of this Indenture shall control.

 

SECTION 15.10.         New
York Law to Govern. This Indenture, the Securities of any series and the Guarantees, if any, shall each be deemed to be a
contract under the laws of the State of New York, and for all purposes shall be construed in accordance with the laws of the State
of New York, but without giving effect to applicable principles of conflicts of law to the extent that the application of the
law of another jurisdiction would be required thereby.

 

SECTION 15.11.         Waiver
of Jury Trial. Each party hereto hereby waives, and each Holder by acceptance of its Securities shall be deemed to have waived,
to the fullest extent permitted by applicable law, any right it may have to a trial by jury (but no other judicial remedies) in
respect of any litigation directly or indirectly arising out of, under or in connection with this Indenture or the transactions
contemplated hereby.

 

SECTION 15.12.         Consent
to Jurisdiction and Service. The Company and each Guarantor, if any, irrevocably (a) agree that any legal suit, action or
proceeding against the Company or any Guarantor arising out of or based upon this Indenture, the Notes or any Guarantee or the
transactions contemplated hereby may be instituted in any U.S. Federal or state court in the City and County of New York (collectively,
the “Specified Courts”) and (b) waive, to the fullest extent they may effectively do so, any objection which they
may now or hereafter have to the laying of venue of any such proceeding. The Company and each Guarantor hereby appoint C T Corporation
System, 111 Eighth Avenue, New York, New York, 10011, as their authorized agent (the “Authorized Agent”) upon whom
process may be served in any such action arising out of or based on this Indenture, the Securities or the transactions contemplated
hereby which may be instituted in any Specified Court, expressly consent to the jurisdiction of any such Specified Court in respect
of any such action, and waive any other requirements of or objections to personal jurisdiction with respect thereto. Such appointment
shall be irrevocable by the Company and any Guarantors. The Company and each Guarantor represent and warrant that the Authorized
Agent has agreed to act as such agent for service of process and agree to take any and all action, including the filing of any
and all documents and instruments, that may be necessary to continue such appointment in full force and effect as aforesaid. Service
of process upon the Authorized Agent in any manner permitted by applicable law and written notice of such service to the Company
or to a Guarantor shall be deemed, in every respect, effective service of process upon the Company or such Guarantor.

 

SECTION 15.13.         Third
Party Beneficiaries. Holders of Securities of the Company are third party beneficiaries of this Indenture, and any of them
(or their representative) shall have the right to enforce the provisions of this Indenture that benefit such Holders.

 

SECTION 15.14.         Counterparts.
This Indenture may be executed in any number of counterparts, each of which shall be an original; but such counterparts shall
together constitute but one and the same instrument.

 

SECTION 15.15.         Effect
of Headings, Table of Contents. The Article and Section headings herein and the Table of Contents are for convenience only
and shall not affect the construction hereof.

 

SECTION 15.16.         No
Adverse Interpretation of Other Agreements. This Indenture may not be used to interpret another indenture, loan or debt agreement
of the Company, any Guarantor or any Subsidiary. Any such indenture, loan or debt agreement may not be used to interpret this
Indenture.

 

SECTION 15.17.         Severability.
If any provision hereof shall be held to be invalid, illegal or unenforceable under applicable law, then the remaining provisions
hereof shall be construed as though such invalid, illegal or unenforceable provision were not contained herein.

 

    	 	-43-	 

     

    

 

SECTION 15.18.         Patriot
Act Compliance. The parties hereto acknowledge that in accordance with Section 326 of the USA Patriot Act the Trustee, like
all financial institutions, is required to obtain, verify, and record information that identifies each person or legal entity
that establishes a relationship or opens account with the Trustee. The parties to this Indenture agree that they will provide
the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the USA Patriot Act.

 

SECTION 15.19.         Force
Majeure. In no event shall the Trustee, Registrar or Paying Agent be liable for any failure or delay in the performance of
its obligations hereunder because of circumstances beyond the Trustee’s, Registrar’s or Paying Agents’ control,
including, but not limited to, acts of God, flood, war (whether declared or undeclared), terrorism, fire, riot or embargo, which
delay, restrict or prohibit the providing of the services contemplated by this Indenture.

 

    	 	-44-	 

     

    

 

SIGNATURES

 

IN WITNESS WHEREOF, the parties
hereto have caused this Indenture to be duly executed, all as of [●].

 

	 	LION BIOTECHNOLOGIES, INC.
	 	as the Company
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	[●]
	 	as a Guarantor
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page
to Base Indenture]

 

     

     

    

 

	 	[●],
	 	as the Trustee
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page
to Base Indenture]

 

     

     

    

 

Schedule I

 

	Company	 	Address and Facsimile Number
	Lion Biotechnologies, Inc.	 	999 Skyway Road, Suite 150

San Carlos, California 94070

(650) 260-7120

Attn:  [●]

 

	Guarantor	 	Address and Facsimile Number
	[●]	 	[●]Exhibit
10.1

 

NOTE
AND WARRANT PURCHASE AGREEMENT

 

This
Note and Warrant Purchase Agreement, dated as of December 22,
2016 (this “Agreement”), is entered into by and among Oncobiologics,
Inc., a Delaware corporation (the “Company”), and the persons and entities listed on the
schedule of purchasers attached hereto as Schedule I (each a “Purchaser” and, collectively, the
“Purchasers”), as such Schedule I may be amended in accordance with Sections 1(c)
and Section 7 hereof.

 

RECITALS

 

A.           The
Company has authorized the sale and issuance of secured promissory notes in the form of Exhibit A
hereto (each, a “Note” and, collectively, the “Notes”) having an
aggregate principal amount of up to Ten Million Dollars ($10,000,000.00) (the “Aggregate Note Amount”),
which Aggregate Note Amount may be increased by the Company upon the consent of the Majority Holders (as defined below).

 

B.           The
Company has prior to the date hereof issued to certain of the Purchasers promissory notes (the “Existing Notes”)
having an aggregate principal amount of $1,350,000 and in connection with the execution of this Agreement, the Company and such
Purchasers are exchanging the Existing Notes for the Notes (without premium or any other consideration in addition to the exchange
thereof).

 

C.           Subject
to the terms and conditions set forth herein, each Purchaser is willing to purchase from the Company, and the Company is willing
to sell to such Purchaser, a Note in the principal amount set forth opposite such Purchaser’s name on Schedule I
hereto together with related warrants to acquire shares of the Company’s common stock.

 

D.           Capitalized
terms not otherwise defined herein shall have the meaning set forth in the Note (as defined below) attached as Exhibit A
hereto.

 

AGREEMENT

 

Now,
Therefore, for good and valuable consideration, the receipt and sufficiency of which
is acknowledged and agreed, and in consideration of the foregoing, and the representations, warranties, covenants and conditions
set forth below, the Company and each Purchaser, intending to be legally bound, hereby agree as follows:

 

1.           The
Notes and Warrants.

 

(a)  Issuance
of Notes. Subject to the terms and conditions hereof, the Company agrees to issue and sell to each of the Purchasers, and
each of the Purchasers agrees to purchase a Note in the principal amount set forth opposite such Purchaser’s name on Schedule
I hereto. The obligations of the Purchasers to purchase Notes are several and not joint. The Aggregate Note Amount may be
increased by the Company upon the consent of the Majority Holders (as defined below).

 

 (b)  Issuance
of Warrants. Concurrently with the issuance of the Notes to each of the Purchasers, the Company will issue to each of the
Purchasers a warrant in the form attached hereto as Exhibit B (each,
a “Warrant” and, collectively, the “Warrants” and together with the Notes,
the “Securities”) to purchase shares of Common Stock of the Company in an amount set forth opposite
such Purchaser’s name on Schedule I hereto.

 

(c)  Delivery.
The sale and purchase of the Securities shall take place at a closing (the “Closing”) to be held
at such place and time as the Company and the Purchasers may determine (the “Closing Date”). At the
Closing, the Company shall deliver to each of the Purchasers the Note and Warrant to be purchased by such Purchaser, against
receipt by the Company of the corresponding purchase price therefore set forth on Schedule I hereto (the “Purchase
Price”). Each of the Securities will be registered in such Purchaser’s name in the Company’s
records.

 

     

     

    

 

(d)  Exchange,
At the Closing, certain Purchasers will exchange the Existing Notes (and all accrued and unpaid interest thereon) for new Notes
(the “Exchange”) and Warrants as set forth on Schedule I, provided that such exchange
for Existing Notes shall not be at a discount, premium or require additional consideration in cash or kind.

 

(e)      Subsequent
Sales. At any time on or before the 90th day following the Closing or at such later time as the Company and the Majority Holders
(as defined below) may mutually agree, the Company may sell up to the balance of the Aggregate Note Amount not sold at the Closing
to such persons as may be approved by the Company (the “Additional Purchasers”). All such sales made
at any additional closings (each an “Additional Closing”), shall be made on the terms and conditions
set forth in this Agreement, and (i) the representations and warranties of the Company set forth in Section 2 hereof
shall speak as of the Closing and the Company shall have no obligation to update any such disclosure, and (ii) the representations
and warranties of the Additional Purchasers in Section 3 hereof shall speak as of such Additional Closing. Schedule
I may be amended by the Company without the consent of the Purchasers to include any Additional Purchasers upon the execution
by such Additional Purchasers of a counterpart signature page hereto. Any Notes sold pursuant to this Section 1(e)
shall be deemed to be “Notes” for all purposes under this Agreement and any Additional Purchasers thereof shall
be deemed to be “Purchasers” for all purposes under this Agreement. Notwithstanding anything to the contrary contained
in this Agreement, any Notes issued to Additional Purchasers shall be in the same form attached hereto as Exhibit A
hereto and no consideration shall be offered or paid to any Additional Purchasers to purchase Securities that
is not offered or paid to all Purchasers under this Agreement. Additionally, no consideration or discount shall be offered
or paid to any Persons to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the
same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision
constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended
for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or
as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

(f)  Use
of Proceeds. The proceeds of the sale and issuance of the Securities shall be used to repay existing loans 7xx143 and
7xx154 from Northfield Bank pursuant to those certain payoff letters attached as Schedule III hereto and for general corporate
purposes, including working capital.

 

(g)  Payments.
All payments on account of the Notes (whether for principal, interest or otherwise) shall be made on a pro rata basis to the Purchasers
in accordance with the respective outstanding principal amounts of their Notes. The Company shall not purchase or redeem any of
the Notes unless an offer on the same terms is made to all Purchasers.

 

2.           Representations
and Warranties of the Company. The Company represents and warrants to each Purchaser that except as otherwise described in
the Company’s registration statement (File No. 333-209011), including a prospectus, as amended at the time it became effective
on May 12, 2016, including the information deemed pursuant to Rule 430A, 430B or 430C under the Securities Act of 1933, as amended
or any successor statute, and the rules and regulations promulgated thereunder (the “1933 Act”) to be
part of such registration statement at the time of its effectiveness (the “IPO Registration Statement”)
and the Company’s filings pursuant to the Securities Exchange Act of 1934, as amended, or any successor statute, and the
rules and regulations promulgated thereunder (the “1934 Act”) (collectively, the “SEC Filings”),
which qualify these representations and warranties in their entirety:

 

(a)  Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business
as now conducted and to own or lease its properties. The Company is duly qualified to do business as a foreign corporation and
is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such
qualification or leasing necessary unless the failure to so qualify has not had and could not reasonably be expected to have a
material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or otherwise) or business
of the Company and its subsidiaries taken as a whole,

 

     

     

    

 

(ii) the
legality, validity or enforceability of any of the Transaction Documents (as defined in Section 5(e)) or (iii) the
ability of the Company to perform its obligations under the Transaction Documents (a “Material Adverse Effect”).
Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the1933 Act,
has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited
liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and
has the power and authority (corporate or other) to carry on its business as now conducted and to own or lease its properties.
Each of the Company’s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company,
as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership
or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and could not
reasonably be expected to have a Material Adverse Effect. All of the issued and outstanding capital stock or other equity or ownership
interests of each of the Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable
and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien,
encumbrance or adverse claim.

 

(b)  Authority.
The Company has the requisite corporate power and authority and has taken all requisite corporate action necessary for, and no
further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution
and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company hereunder
or thereunder, and (iii) the authorization, issuance and delivery of the Securities. The Transaction Documents constitute
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating
to or affecting creditors’ rights generally and to general equitable principles.

 

(c)  No
Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Securities in accordance with the provisions thereof will not, except for such violations,
conflicts or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect,
(i) conflict with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default under,
the Company’s Certificate of Incorporation or Bylaws, both as in effect on the date hereof (true and complete copies of
which have been made available to the Purchasers through the EDGAR system), or (b) assuming the accuracy of the representations
and warranties in Section 3, any applicable statute, rule, regulation or order of any governmental agency or body
or any court, domestic or foreign, having jurisdiction over the Company or its subsidiaries, or any of their assets or properties,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company
or its subsidiaries or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any contract the termination of which would reasonably be expected to have a Material Adverse Effect.

 

(d)  Consents.
The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Securities
require no consent of, action by or in respect of, or filing with, any person or entity, governmental body, agency, or official
other than filings that have been made pursuant to applicable state securities laws and the rules and regulations of Nasdaq, or
such post-sale filings pursuant to applicable state and federal securities laws and the rules and regulations of Nasdaq that the
Company undertakes to file within the applicable time periods.

 

(e)  No
Violation or Default. The Company is not (i) in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received
notice of a claim that it is in

 

     

     

    

 

default
under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it
is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) in
violation of any judgment, decree or order of any court, arbitrator or governmental body or (iii) in violation of any statute,
rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local
laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and
labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(f)  Litigation.
Except as described in the SEC Filings, there are no legal, governmental or regulatory investigations, actions, suits or proceedings
pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property
of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely
to the Company or its subsidiaries, could (i) reasonably be expected to have a Material Adverse Effect or (ii) adversely affect
or challenge the legality, validity or enforceability of the Transaction Documents.

 

(g)  Title.
Except as disclosed in the SEC Filings, the Company and its subsidiaries have good and marketable title to all real properties
and all other properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and except as disclosed in the
SEC Filings, the Company and its subsidiaries hold any leased real or personal property under valid, subsisting and enforceable
leases with which the Company are in compliance and with no exceptions, except such as would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect.

 

(h)  Intellectual
Property. Except as expressly contemplated by the SEC Filings, the Company and its subsidiaries own, possess, license or have
other rights to use, the patents and patent applications, copyrights, trademarks, service marks, trade names, service names and
trade secrets described in the SEC Filings as being owned, possessed, licensed or otherwise having rights to use in connection
with its business and that the failure to so have would have or reasonably be expected to result in a Material Adverse Effect
(collectively, the “Intellectual Property Rights”). There is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by any person or entity that the Company’s business or the business of its
subsidiaries as now conducted or as contemplated to be conducted as described by the SEC Filings infringes or otherwise violates
any patent, trademark, copyright, trade secret or other proprietary rights of another. To the Company’s knowledge,
the Intellectual Property Rights are enforceable and there is no existing infringement by another person or entity of any of the
Intellectual Property Rights that would have or would reasonably be expected to have a Material Adverse Effect. The Company and
its subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of its Intellectual
Property Rights, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.

 

(i)  Financial
Statements. The financial statements included in each SEC Filing comply in all material respects with applicable accounting
requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent
corrected by a subsequent restatement) and present fairly, in all material respects, the financial position of the Company as
of the dates shown and its results of operations and cash flows for the periods shown, subject in the case of unaudited financial
statements to normal, immaterial year-end audit adjustments, and such financial statements have been prepared in conformity with
United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”)
(except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain
all footnotes

 

     

     

    

 

required
by GAAP, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). Except as set forth
in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not incurred
any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and
nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have
had or would reasonably be expected to have a Material Adverse Effect.

 

(j)  Sarbanes-Oxley;
Internal Accounting Controls. The Company and the subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Securities and Exchange Commission (“Commission”) thereunder that are effective as of the date
hereof and as of the Closing Date. The Company and the subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP
and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company and the subsidiaries have established disclosure
controls and procedures (as defined in the 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and the subsidiaries and designed
such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files
or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms. The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures
of the Company and the subsidiaries as of the end of the period covered by the most recently filed periodic report under the 1934
Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report
under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control
over financial reporting (as such term is defined in the 1934 Act) that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its subsidiaries.

 

(k)  Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any subsidiaries to any
broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person or entity with respect
to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees
or with respect to any claims made by or on behalf of other persons or entities for fees of a type contemplated in this Section
that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(l)  Solvency.
Based on the consolidated financial condition of the Company as of the initial Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder: (i) the fair saleable value of the Company’s
assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing

 

     

     

    

 

and
amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which
lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction
within one year from the initial Closing Date. Schedule II sets forth as of the date hereof, after giving effect
to the transactions contemplated herein, all outstanding secured and unsecured Indebtedness of the Company or any subsidiary,
or for which the Company or any subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any subsidiary is in default with respect to any Indebtedness.

 

(m)  Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is
subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the
payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of
the Company or of any subsidiary know of no basis for any such claim.

 

(n)  Foreign
Corrupt Practices. Neither the Company nor any subsidiary, nor to the knowledge of the Company or any subsidiary, any agent
or other person acting on behalf of the Company or any subsidiary, has: (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any
provision of FCPA.

 

(o)  Accountants.
To the knowledge and belief of the Company, such accounting firm: (i) is a registered public accounting firm as required by the
1934 Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company’s Annual
Report for the fiscal year ending September 30, 2016. There are no disagreements of any kind presently existing, or reasonably
anticipated by the Company to arise, between the Company and the accountants formerly or presently employed by the Company and
the Company is current with respect to any fees owed to its accountants which could affect the Company’s ability to perform
any of its obligations under any of the Transaction Documents.

 

(p)  Seniority.
As of the Closing Date, no Indebtedness or other claim against the Company is senior to the Notes in right of payment, whether
with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security
interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as
to the property covered thereby).

 

(q)  FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under
the Federal Food, Drug and Cosmetic Act, as amended, and the

 

     

     

    

 

regulations
thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed
by the Company or any of its subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical
Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with
all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical
practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be
in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its subsidiaries, and none of the Company or any of its subsidiaries has received any notice, warning
letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure,
registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of,
or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension,
or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical
Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its subsidiaries, (iv) enjoins production
at any facility of the Company or any of its subsidiaries, (v) enters or proposes to enter into a consent decree of permanent
injunction with the Company or any of its subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect.
The properties, business and operations of the Company have been and are being conducted in all material respects in accordance
with all applicable laws, rules and regulations of the FDA.  The Company has not been informed by the FDA that the FDA will
prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed
by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or
proposed to be developed by the Company.

 

(r)  Office
of Foreign Assets Control. Neither the Company nor any subsidiary nor, to the Company's knowledge, any director, officer,
agent, employee or affiliate of the Company or any subsidiary is currently subject to any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(s)  U.S.
Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

 

(t)  Bank
Holding Company Act. Neither the Company nor any of its subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). For purposes of this Agreement, “Affiliate”
means, with respect to any Person, another person controlling, controlled by or under common control with, such Person. Neither
the Company nor any of its subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity
that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its subsidiaries or Affiliates
exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation
by the Federal Reserve.

 

(u)  Money
Laundering. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable

 

     

     

    

 

money
laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any subsidiary,
threatened.

 

(v)  SEC
Filings.

 

(i)  The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under 1933
Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the
date hereof (or such shorter period as the Company was required by law or regulation to file such material). At the time of filing
thereof, the SEC Filings complied as to form in all material respects with the requirements of the 1933 Act or 1934 Act, as applicable,
and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.

 

(ii)  Each
prospectus filed pursuant to Rule 424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities
pursuant thereto, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading.

 

(iii)  Except
for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its subsidiaries
or their respective businesses, properties, operations, assets or financial condition, that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least 1 business day prior to the date that this representation is made.

 

3.           Representations
and Warranties of Purchasers. Each Purchaser represents and warrants, severally and not jointly, to the Company as follows:

 

(a)  Binding
Obligation. Such Purchaser has full legal capacity, power and authority to execute and deliver this Agreement and to perform
its obligations hereunder. This Agreement and the Transaction Documents constitute valid and binding obligations of such Purchaser,
enforceable in accordance with their terms, except as limited by bankruptcy, insolvency or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

(b)  Securities
Law Compliance. Such Purchaser has been advised that the Securities have not been registered under the 1933 Act or
any state securities laws and, therefore, cannot be resold unless they are registered under the 1933 Act and applicable state
securities laws or unless an exemption from such registration requirements is available. Such Purchaser is aware that the Company
is under no obligation to effect any such registration with respect to the Securities or to file for or comply with any
exemption from registration. Such Purchaser has not been formed solely for the purpose of making this investment and is
purchasing the Securities to be acquired by such Purchaser hereunder for its own account for investment, not as
a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and such Purchaser has
no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933
Act. Such Purchaser has such knowledge and experience in financial and business matters that such Purchaser is capable
of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing such
Purchaser’s

 

     

     

    

 

financial
condition and is able to bear the economic risk of such investment for an indefinite period of time. Such Purchaser is an accredited
investor as such term is defined in Rule 501 of Regulation D under the 1933 Act and shall submit to the Company such
further assurances of such status as may be reasonably requested by the Company. The residency of such Purchaser (or, in the case
of a partnership or corporation, such entity’s principal place of business) is correctly set forth beneath such Purchaser’s
name on Schedule I hereto

 

(c)  Access
to Information. Such Purchaser hereby: (a) acknowledges that such Purchaser has received all the information such Purchaser
has requested from the Company and that such Purchaser considers necessary or appropriate for deciding whether to acquire the
Securities; and (b) represents that such Purchaser has had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of the Securities and to obtain any additional information necessary
to verify the accuracy of the information given such Purchaser.

 

(d)  Tax
Advisors. Such Purchaser has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences
of this investment and the transactions contemplated by this Agreement. With respect to such matters, such Purchaser relies solely
on any such advisors and not on any statements or representations of the Company or any of its agents, written or oral. Such Purchaser
understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment
and the transactions contemplated by this Agreement.

 

4.           Covenants
of the Company. 

 

(a)  Payments.
Notwithstanding anything to the contrary in the Notes, prior to the termination or satisfaction in full of the Notes the Company
hereby agrees that it shall not (i) make any payments to Company officers with respect to Company indebtedness owed to
such officers, (ii) make any distribution or dividend payments to stockholders of the Company or redeem or retire for
value any shares of any class of stock of the Company or (iii) except as permitted pursuant to Section 4(g), repay,
repurchase or offer to repay, repurchase or otherwise acquire any Indebtedness, other than the Notes if on a pro-rata basis and
other than regularly scheduled principal and interest payments as such terms are in effect as of the date hereof, provided that
such payments shall not be permitted if, at such time, or after giving effect to such payment, any Event of Default (as defined
in the Notes) shall occur. For the avoidance of doubt, no payments (on account of principal interest or otherwise) with respect
to the Indebtedness listed under the heading “Investor Notes” on Schedule II hereto shall be made prior to the payment
in full of the obligations under the Notes.

 

(b)  Indebtedness.
The Company shall not incur, suffer or permit to exist any Indebtedness other than (i) the indebtedness outstanding on the
date hereof and set forth on Schedule II hereto; (ii) indebtedness evidenced by the Notes; and (iii) indebtedness of the
type described in clause (c) of the definition of “Permitted Liens” as such term is defined in the Security Agreement.

 

(c)  Liens.
The Company shall not incur, suffer or permit to exist any Lien (as defined in the Security Agreement) other than Permitted
Liens (as defined in the Security Agreement).

 

(d)  Affiliate
Transactions. The Company shall not enter into any transaction with any Affiliate of the Company which would be required to
be disclosed in any public filing with the Commission, unless such transaction is made on an arm’s-length basis and expressly
approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required for board
approval).

 

(e)  Publicity.
The Company shall (a) by 9:30 a.m. (New York City time) on the business day immediately following the date hereof, issue a press
release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including
the Transaction Documents as exhibits thereto, with the Commission within the time required by the 1934 Act.

 

     

     

    

 

(f)  Use
of Proceeds. Except as set forth on Schedule IV attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any
portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business
and prior practices), (b) for the redemption of any equity or equity equivalents of the Company or any of its subsidiaries or
to make any distribution or dividend to any stockholders of the Company, (c) for the settlement of any outstanding litigation
or (d) in violation of applicable law.

 

(g)  Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be
disclosed pursuant to Section  4(e), the Company represents, warrants, covenants and agrees that neither it, nor any
other Person acting on its behalf has provided, or will provide any Purchaser or its agents or counsel with any information that
constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser
shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The
Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser’s
consent, the Company hereby covenants and agrees that such purchaser shall not have any duty of confidentiality to Company, any
of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company,
and of its subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law.

 

5.           Conditions
to Closing of the Purchasers. Each Purchaser’s obligations at the Closing are subject to the fulfillment, on or prior
to the Closing Date, of all of the following conditions, any of which may be waived in whole or in part by such Purchaser:

 

(a)  Representations
and Warranties. The representations and warranties made by the Company in Section 2 hereof shall have been true
and correct when made, and shall be true and correct on the Closing Date.

 

(b)  Governmental
Approvals and Filings. Except for any notices required or permitted to be filed after the Closing Date with certain federal
and state securities commissions, the Company shall have obtained all governmental approvals required in connection with the lawful
sale and issuance of the Securities.

 

(c)  Legal
Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the Purchasers, of the Securities
shall be legally permitted by all laws and regulations to which the Purchasers or the Company are subject.

 

(d)  Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all
documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the Purchasers.

 

(e)  Transaction
Documents. The Company shall have duly executed and delivered to the Purchasers the following documents (collectively, the
“Transaction Documents”): (i) this Agreement; (ii) the Security Agreement in the form of Exhibit
C hereto (the “Security Agreement”), (iii) the Intellectual Property Security
Agreement in the form of Exhibit D
hereto (the “IP Security Agreement”) and (iv) such Purchaser’s Securities issued hereunder.

 

(f)  Minimum
Principal. The aggregate purchase price at the initial Closing shall not be less than $6,500,000.

 

     

     

    

 

(g)  Deliveries.
The Company shall have delivered to each Purchaser the following:

 

(i)        Such
Purchaser’s Note, duly executed;

 

(ii)       Such
Purchaser’s Warrant, duly executed;

 

(iii)       the
Security Agreement and the IP Security Agreement, each duly executed by the Company; 

 

(iv)      a
legal opinion of Company counsel reasonably satisfactory in form and substance to such Purchaser; and

 

(v)      a
subordination agreement, reasonably satisfactory in form and substance to such Purchaser, duly executed by certain holders of
existing Indebtedness of the Company.

 

6.           Conditions
to Obligations of the Company. The Company’s obligation to issue and sell the Securities at the Closing is subject
to the fulfillment, on or prior to the Closing Date, of the following conditions, any of which may be waived in whole or in part
by the Company:

 

(a)  Representations
and Warranties. The representations and warranties made by the applicable Purchaser in Section 3 hereof shall
be true and correct when made, and shall be true and correct on the Closing Date.

 

(b)  Governmental
Approvals and Filings. Except for any notices required or permitted to be filed after the Closing Date with certain federal
and state securities commissions, the Company shall have obtained all governmental approvals required in connection with the lawful
sale and issuance of the Securities.

 

(c)  Legal
Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the applicable Purchasers, of the
Securities shall be legally permitted by all laws and regulations to which such Purchasers or the Company are subject.

 

(d)  Purchase
Price. Each Purchaser shall have delivered to the Company the Purchase Price in respect of the Securities being purchased
by such Purchaser referenced in Section 1(c) hereof.

 

7.           Miscellaneous.

 

(a)  Waivers
and Amendments. Except as set forth in Section 8 of the Security Agreement, any provision of this Agreement, the Security
Agreement, the IP Security Agreement and the Securities may be amended, waived or modified only upon the written consent of the
Company and Purchasers holding greater than sixty-seven percent (67%) of the outstanding and unpaid principal of all Notes (the
“Majority Holders”); provided that for so long as Sabby (as defined below) and PointState Fund LP (“PointState”)
shall hold any Notes, the term Majority Holders shall include Sabby and PointState. Any amendment or waiver effected in accordance
with this paragraph shall be binding upon each holder of any Securities.

 

(b)  Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement and all actions arising out of or in connection with this
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to
the conflicts of law provisions. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of
the State of New York located in New York County and the United States District Court for the Southern District of New York for
the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated
hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere
in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably
consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.
Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such
courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in
an inconvenient forum.

 

     

     

    

 

EACH
OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS
THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

(c)  Survival.
The representations, warranties, covenants and agreements made herein shall survive the execution and delivery of this Agreement.

 

(d)  Successors
and Assigns. Subject to the restrictions on transfer described in Sections 7(e) and 7(f) below,
the rights and obligations of the Company and the Purchasers shall be binding upon and benefit the successors, assigns, heirs,
administrators and transferees of the parties.

 

(e)  Registration,
Transfer and Replacement of the Notes. The Notes issuable under this Agreement shall be registered notes. The Company will
keep, at its principal executive office, books for the registration and registration of transfer of the Notes. Prior to presentation
of any Note for registration of transfer, the Company shall treat the person or entity in whose name such Note is registered as
the owner and holder of such Note for all purposes whatsoever, whether or not such Note shall be overdue, and the Company shall
not be affected by notice to the contrary. Subject to any restrictions on or conditions to transfer set forth in any Note, the
holder of the Note, at its option, may in person or by duly authorized attorney surrender the same for exchange at the Company’s
executive offices, and promptly thereafter and at the Company’s expense, except as provided below, receive in exchange therefor
one or more new Note(s), each in the principal requested by such holder, dated the date to which interest shall have been paid
on the Note so surrendered or, if no interest shall have yet been so paid, dated the date of the Note so surrendered and registered
in the name of such person or entity or person or entitys as shall have been designated in writing by such holder or its attorney
for the same principal amount as the then unpaid principal amount of the Note so surrendered. Upon receipt by the Company of evidence
reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note and (a) in the
case of loss, theft or destruction, of indemnity reasonably satisfactory to it; or (b) in the case of mutilation, upon surrender
thereof, the Company, at its expense, will execute and deliver in lieu thereof a new Note executed in the same manner as the Note
being replaced, in the same principal amount as the unpaid principal amount of such Note and dated the date to which interest
shall have been paid on such Note or, if no interest shall have yet been so paid, dated the date of such Note.

 

(f)  Assignment
by the Company. The rights, interests or obligations hereunder may not be assigned, by operation of law or otherwise, in whole
or in part, by the Company without the prior written consent of the Majority Holders.

 

(g)  Entire
Agreement. This Agreement together with the other Transaction Documents constitutes and contains the entire agreement between
the Company and the Purchasers and supersedes any and all prior agreements, negotiations, correspondence, understandings and communications
among the parties, whether written or oral, respecting the subject matter hereof.

 

(h)  Notices.
All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall in writing
and faxed, mailed or delivered to each party as follows: (i) if to a Purchaser, at Purchaser’s address or facsimile
number set forth in Schedule I hereto, or at such other address as such Purchaser shall have furnished the Company in writing,
with a copy to Yvan-Claude J. Pierre, Esq., 1114 Cooley LLP, Avenue of the Americas, New York, New York, 10036-7798 (facsimile:
212-479-6275; email: ypierre@cooley.com), and (ii) if to the Company, at the address set forth on the signature page hereto,
or at such other address or facsimile number as the Company shall have furnished to such Purchaser in writing. All such notices
and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered personally,
(iii) one business day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one

 

     

     

    

 

business
day after being deposited with an overnight courier service of recognized standing or (v) four days after being deposited
in the U.S. mail, first class with postage prepaid.

 

(i)  Expenses.
At the Closing, the Company has agreed to reimburse Sabby Management, LLC (“Sabby”) the non-accountable
sum of $40,000 for its legal and due diligence fees and expenses. Except as set forth in this Agreement to the Contrary, the parties
hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions contemplated hereby
are consummated; it being understood that each of the Company and each Purchaser has relied on the advice of its own respective
counsel. Notwithstanding the foregoing, the Company shall pay all fees costs and expenses of Purchasers incurred in connection
with enforcement of any of their rights and remedies hereunder and under the other Transaction Documents.

 

(j)  Additional
Purchasers. At any time and from time to time after the date hereof, with the consent of the Majority Holders, the Company
may issue and sell additional Securities in excess of the Aggregate Note Amount to any person or entity that becomes a
Purchaser hereunder (an “Additional Purchaser”) by signing a joinder agreement substantially in the
form of Exhibit E (a “Joinder Agreement”)
and upon execution of each such Joinder Agreement, Schedule I shall be amended to include the relevant information with
respect to such Additional Purchaser.

 

(k)  Separability
of Agreements. The Company’s agreement with each of the Purchasers is a separate agreement and the sale of the Securities
to each of the Purchasers is a separate sale. Unless otherwise expressly provided herein, the rights of each Purchaser hereunder
are several rights, not rights jointly held with any of the other Purchasers. Any invalidity, illegality or limitation on the
enforceability of this Agreement or any part thereof, by any Purchaser whether arising by reason of the law of the respective
Purchaser’s domicile or otherwise, shall in no way affect or impair the validity, legality and enforceability of this Agreement
with respect to other Purchasers.

 

(l)  Severability
of this Agreement. If any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

(m)  Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together
will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals.

 

(n)  Usury.
To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim,
and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any Action or Proceeding that may be brought by any Purchaser in order to enforce
any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction
Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments
in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”),
and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated
with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed
such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction
Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum
contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective

 

     

     

    

 

date
thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess
of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction Documents,
such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the
Company, the manner of handling such excess to be at such Purchaser’s election.

 

(o)  Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through Ellenoff Grossman & Schole LLP (“EGS”).
EGS does not represent any of the Purchasers and only represents Sabby. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers.

 

(Signature
Page Follows) 

 

     

     

    

 

The parties
have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year
first written above.

 

	 	COMPANY:
	 	 
	 	Oncobiologics, Inc.
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Lawrence A. Kenyon
	 	Name:  Lawrence A. Kenyon
	 	Title: Chief Financial Officer

 

	 	Address:  	7 Clarke Drive
	 	 	Cranbury, New Jersey
	 	 	 
	 	Facsimile:	609-228-4113

 

Signature
page for Note and Warrant Purchase Agreement 

 

     

     

    

 

The parties
have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year
first written above.

 

 

	 	PURCHASERS:
	 	 
	 	 	 

 

	 	By:	 

	 	Name:	 

	 	Title:	 

 

	 	Address:	 

 

	 	Facsimile:	 

 

Signature
page for Note and Warrant Purchase Agreement 

 

     

     

    

 

Exhibit
A

 

THIS
SECURED NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THIS SECURED NOTE MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER
THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES
LAWS.

 

ONCOBIOLOGICS,
INC.

 

FORM
OF SECURED PROMISSORY NOTE

 

	$	 	December 22, 2016
	 	 	Cranbury, New Jersey

 

For
Value Received, Oncobiologics,
Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of [INSERT
NAME] (“Purchaser”), or its registered assigns, in lawful money of the United States of America and
in immediately available funds, the principal sum of [                        ]
Dollars ($      ), together with accrued and unpaid interest thereon, each due and payable
on the date and in the manner set forth below. This Note is issued pursuant to the Note and Warrant Purchase Agreement,
dated December 22, 2016 (the “Purchase Agreement”). Capitalized words used but not otherwise
defined hereunder shall have the meaning ascribed to such terms in the Purchase Agreement.

 

THE
OBLIGATIONS DUE UNDER THIS NOTE ARE SECURED BY A SECURITY AGREEMENT (THE “SECURITY AGREEMENT”) AND AN
INTELLECTUAL PROPERTY SECURITY AGREEMENT (“THE IP SECURITY AGREEMENT”), EACH DATED AS OF THE DATE HEREOF
AND EXECUTED BY THE COMPANY FOR THE BENEFIT OF THE PURCHASER. ADDITIONAL RIGHTS OF THE PURCHASER ARE SET FORTH IN THE SECURITY
AGREEMENT AND THE IP SECURITY AGREEMENT.

 

The
following is a statement of the rights of Purchaser and the conditions to which this Note is subject, and to which Purchaser,
by the acceptance of this Note, agrees:

 

1.           Principal
Repayment. The outstanding principal amount of this Note, and all accrued and unpaid interest thereon, shall be due and payable
on December 22, 2017 (the “Maturity Date”).

 

2.           Interest.
The Company further promises to pay interest on the outstanding principal amount hereof from the date hereof, until payment in
full, which interest shall be payable at the rate of five percent (5.0%) per annum (the “Stated Interest
Rate”) or the maximum rate permissible by law (which under the laws of the State of New York shall be deemed to
be the laws relating to permissible rates of interest on commercial loans), whichever is less. Interest shall accrue daily
be due and payable on the Maturity Date, and shall be calculated on the basis of a 365-day year for the actual number of days
elapsed. Upon the occurrence and during the continuance of an Event of Default, all amounts owing hereunder shall bear interest
at the Stated Interest Rate plus two percent (2%) per annum.

 

     

     

    

 

3.           Place
of Payment. All amounts payable hereunder shall be payable at the office of Purchaser, unless another place of payment shall
be specified in writing by Purchaser. All payments hereunder shall be made without any set-off, counterclaim defenses, withholding
(for taxes or otherwise) or reduction of any kind.

 

4.           Application
of Payments. Payment on this Note shall be applied first to accrued interest and thereafter to the outstanding principal balance
hereof. This Note may be prepaid in whole or in part at any time without penalty or premium. Any interest accrued on the amounts
so prepaid to the date of such prepayment shall be paid at the time of any such prepayment.

 

5.           Event
of Default. Each of the following events shall be an “Event of Default” hereunder:

 

(a)          the
Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and payable or any
accrued interest or other amounts due under this Note on the date the same becomes due and payable;

 

(b)          the
Company shall default in its performance of any other covenant under this Note or any of the Transaction Documents, which default
is not cured within the earlier of (i) five (5) days after notice thereof from Purchaser and (ii) ten (10) days after the Company
has become aware or should have become aware of such failure;

 

(c)          the
Company breaches any representation or warranty contained in this Note or any Transaction Document and such breach adversely affects,
or could reasonably be expected to adversely affect, any of the Purchaser’s rights or obligations under this Note or any
Transaction Document;

 

(d)          a
default or event of default (subject to any grace or cure period provided in the applicable agreement, document or instrument)
shall occur under (A) any of the Transaction Documents or (B) any other material agreement, lease, document or instrument to which
the Company or any subsidiary is obligated;

 

(e)          the
Company or any subsidiary shall default on any of its obligations under any mortgage, credit agreement or other facility, indenture
agreement, factoring agreement or other instrument under which there may be issued, or by which there may be secured or evidenced,
any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation
greater than $150,000, whether such indebtedness now exists or shall hereafter be created, and (b) results in such indebtedness
becoming or being declared due and payable prior to the date on which it would otherwise become due and payable;

 

(f)          the
Company or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) shall be subject to a Bankruptcy
Event. “Bankruptcy Event” means any of the following events: (a) the Company or any Significant Subsidiary
thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of
debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Company or any Significant
Subsidiary thereof, (b) there is commenced against the Company or any Significant Subsidiary thereof any such case or proceeding
that is not dismissed within 60 days after commencement, (c) the Company or any Significant Subsidiary thereof is adjudicated
insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company
or any Significant Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its
property that is not discharged or stayed within 60 calendar days after such appointment, (e) the Company or any Significant Subsidiary
thereof makes a general assignment for the benefit of creditors, (f) the

 

    -2-

     

    

 

Company
or any Significant Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment or restructuring
of its debts, (g) the Company or any Significant Subsidiary thereof admits in writing that it is generally unable to pay its debts
as they become due, (h) the Company or any Significant Subsidiary thereof, by any act or failure to act, expressly indicates its
consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting
any of the foregoing;

 

(g)          the
Company shall be a party to any Change of Control Transaction or shall sell or dispose of all or in excess of 33% of its assets
in one transaction or a series of related transactions (whether or not such sale would constitute a Change of Control Transaction).
“Change of Control Transaction” means the occurrence after the date hereof of any of (a) an acquisition
after the date hereof by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under
the 1934 Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract
or otherwise) of in excess of 33% of the voting securities of the Company, (b) the Company merges into or consolidates with any
other person or entity, or any person or entity merges into or consolidates with the Company and, after giving effect to such
transaction, the stockholders of the Company immediately prior to such transaction own less than 66% of the aggregate voting power
of the Company or the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of its
assets to another person or entity and the stockholders of the Company immediately prior to such transaction own less than 66%
of the aggregate voting power of the acquiring entity immediately after the transaction, or (d) a replacement at one time or within
a three year period of more than one-half of the members of the board of directors which is not approved by a majority of those
individuals who are members of the board of directors on the original issue date of this Note (or by those individuals who are
serving as members of the board of directors on any date whose nomination to the board of directors of the Company was approved
by a majority of the members of the board of directors who are members on the date hereof); or

 

(h)          any
monetary judgment, writ or similar final process shall be entered or filed against the Company, any subsidiary or any of their
respective property or other assets for more than $50,000, and such judgment, writ or similar final process shall remain unvacated,
unbonded or unstayed for a period of 45 calendar days.

 

Upon
the occurrence of an Event of Default hereunder, all unpaid principal, accrued interest and other amounts owing hereunder shall,
automatically, be immediately due, payable and collectible by Purchaser. In connection with such acceleration described herein,
the Purchaser need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and
the Purchaser may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder
and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Purchaser at any
time prior to payment hereunder and the Purchaser shall have all rights as a holder of the Note until such time, if any, as the
Purchaser receives full payment pursuant to this Section 7. No such rescission or annulment shall affect any subsequent Event
of Default or impair any right consequent thereon.

 

6.           Waivers.
The Company (i) waives presentment, demand, protest or notice of any kind in connection with this Note and (ii) agrees, in the
event of an Event of Default, to pay to the Purchaser of this Note, on demand, all costs and expenses (including reasonable legal
fees and expenses as and when incurred), incurred in connection with the enforcement and/or collection of this Note. The right
to plead any and all statutes of limitations as a defense to any demands hereunder is hereby waived to the full extent permitted
by law.

 

    -3-

     

    

 

7.           Notices.
All notices and other communications required to be given under this Note to either Purchaser or the Company, as applicable,
shall be in writing and faxed, mailed or delivered to each party at the respective addresses of the parties as set forth in the
Purchase Agreement, or at such other address or facsimile number as the Company shall have furnished to such Purchaser in writing.
All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered
personally, (iii) one business day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one
business day after being deposited with an overnight courier service of recognized standing or (v) four days after being
deposited in the U.S. mail, first class with postage prepaid.

 

8.           Governing
Law. This Note shall be governed by and construed under the laws of the State of New York, as applied to agreements among
New York residents, made and to be performed entirely within the State of New York, without giving effect to conflicts of laws
principles. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York
located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit,
action, proceeding or judgment relating to or arising out of this Note and the transactions contemplated hereby. Service of process
in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods
as are specified for the giving of notices under this Note. Each of the parties hereto irrevocably consents to the jurisdiction
of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably
waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives
any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH
OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS
THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

9.           Amendments.
No amendment, modification or waiver of any provision of this Note nor consent to departure by the Company therefrom shall
be effective, irrespective of any course of dealing, unless the same shall be in writing and signed by the Company and the Majority
Holders (which shall be binding on Purchaser whether or not signed by Purchaser) and then such waiver or consent shall be effective
only in the specific instance and for the specific purpose for which given. Notwithstanding the foregoing, the consent of the
Purchaser shall be necessary to do the following to the Note:

 

(a)          reduce
the percentage of the principal and interest amount of Notes whose holders must consent to constitute Majority Holders’
consent;

 

(b)          reduce
the rate of or change the time for payment of interest on the Note;

 

(c)          reduce
the principal of or change the fixed maturity of the Note; or

 

(d)          make
the Note payable in money other than lawful money of the United States of America and in immediately available funds.

 

10.         Successors
and Assigns. This Note may be transferred only in compliance with the provisions herein and upon its surrender to the Company
for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory
to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like
principal amount and interest shall be issued to, and registered in the name of, the transferee. Interest and principal shall
be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company’s obligation
to pay such interest and principal.

 

11.         Board
Authorization; Intended Purposes. All corporate action on the part of the Company, its directors and its stockholders, necessary
for the authorization, execution, delivery and performance of this Note by the Company and the performance of the Company’s
obligations hereunder, has been taken. The Company will use all of the proceeds from this Note for operations of its business.

 

12.         Counterparts.
This Note may be executed in any number of counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one
and the same Note.

 

13.         Registered
Form. This Note is in registered form within the meaning of 26 C.F.R. Section 1.871-14(c)(1)(i) for United States federal
income and withholding tax purposes. This Note may be transferred only upon its surrender to the Company for registration of transfer,
duly endorsed, or

 

    -4-

     

    

 

accompanied
by a duly executed written instrument of transfer in form reasonably satisfactory to the Company. Thereupon, this Note shall be
reissued to, and registered in the name of, the transferee, or a new Note for like principal amount and interest shall be issued
to, and registered in the name of, the transferee.

 

14.         Absolute
Obligation. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company,
which is absolute and unconditional, to pay the principal of, liquidated damages and accrued interest, as applicable, on this
Note at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the
Company. This Note ranks pari passu with all other Notes now or hereafter issued under the terms set forth herein.

 

15.         Secured
Obligation. The obligations of the Company under this Note are secured by all assets of the Company pursuant to the Security
Agreement and IP Security Agreement, each dated as of December   , 2016 between the Company and the Purchasers
signatory thereto.

 

(Signature
Page Follows)

 

    -5-

     

    

 

The Company
has caused this Note to be issued as of the date first written above.

 

 

	 	Oncobiologics, Inc.	 
	 	a Delaware corporation	 
	 	 	 	 
	 	 	 	 
	 	By:	                          	 

	 	Name:	Lawrence A. Kenyon	 

	 	Title:	Chief Financial Officer	 

 

     

     

    

 

EXHIBIT
B

 

FORM OF WARRANT

 

NEITHER THIS SECURITY NOR
THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

oncobiologics,
inc.

 

	Warrant Shares: _______	Initial Exercise Date: December 22, 2016

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five
year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for
and purchase from Oncobiologics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject
to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (“Common Stock”).
The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section
2(b).

 

Section 1.          Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section
1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

    	 	1	 

     

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Liens”
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing.

 

“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15th Avenue, Brooklyn, New York 11219 and a facsimile number of 718.765.8713, and any successor transfer
agent of the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the

 

    	 	2	 

     

    

 

fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

Section 2.         Exercise.

 

a)       Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company or the Transfer Agent (or
such other office or agency that the Company may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company), as applicable, of a duly executed facsimile copy or PDF copy submitted by electronic
(or e-mail attachment) of the Notice of Exercise in the form annexed hereto. Within the earlier of (i) three (3) Trading Days and
(ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable
Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure
specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which
case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total
number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within two (2) Business Days of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.

 

b)       Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $3.00, subject to adjustment hereunder
(the “Exercise Price”).

 

c)       Cashless
Exercise. If at any time after the six-month anniversary of the Initial Exercise Date, there is no effective Registration Statement
registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also
be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled
to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

    	 	3	 

     

    

 

(A) =  the last
VWAP immediately preceding the time of delivery of the Notice of Exercise giving rise to the applicable “cashless exercise”,
as set forth in the applicable Notice of Exercise (to clarify, the “last VWAP” will be the last VWAP as calculated
over an entire Trading Day such that, in the event that this Warrant is exercised at a time that the Trading Market is open, the
prior Trading Day’s VWAP shall be used in this calculation);

 

(B) =  the Exercise
Price of this Warrant, as adjusted hereunder; and

 

(X) =  the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees not to
take any position contrary to this Section 2(c).

 

		d)	Mechanics of Exercise.

 

i.            Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through
its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and
either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144, and otherwise by book-entry, registered in the Company’s share register in the name of the Holder or
its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i) three (3) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of
the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case
of a cashless exercise) is received within the earlier of (i) three Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to
the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share

 

    	 	4	 

     

    

 

Delivery Date,
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day
after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.
As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of
Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.

 

ii.          Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.         Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.         Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not

 

    	 	5	 

     

    

 

honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

v.           No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.         Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that in the event Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.

 

vii.         Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    	 	6	 

     

    

 

e)       Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
of the Beneficial Ownership Limitation is being made, but shall exclude the number of shares of Common Stock that would
be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of
its Affiliates or Attribution Parties but not permitted to be exercised due to the Beneficial Ownership Limitation and
(ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without
limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in
the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this Warrant or any portion thereof is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) shall be the sole
responsibility of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant or any portion thereof is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties), in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within two
Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case,
the number

 

    	 	7	 

     

    

 

of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of
this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section
2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant. Notwithstanding anything to
the contrary contained in this Warrant, no party may waive the Beneficial Ownership Limitation.

 

Section
3.             Certain Adjustments.

 

a)           Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)           [RESERVED]

 

c)           Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock

 

    	 	8	 

     

    

 

Equivalents or
rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common
Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such
Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).]

 

d)       Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

e)       Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of

 

    	 	9	 

     

    

 

Common Stock are
permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group
of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder
of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of
a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion
of this Warrant on the date of the consummation of such Fundamental Transaction. “Black Scholes Value” means
the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg,
L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility
equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately
following the public

 

    	 	10	 

     

    

 

announcement of
the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds within five Business Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the
relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents
with the same effect as if such Successor Entity had been named as the Company herein.

 

f)             Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)           Notice
to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the

 

    	 	11	 

     

    

 

number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.         Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email
to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such
notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

Section 4.            Transfer
of Warrant.

 

a)          Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed

 

    	 	12	 

     

    

 

by the Holder or
its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.

 

b)       New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)       Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

d)       Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does
not require registration under the Securities Act.

 

e)       Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

    	 	13	 

     

    

 

Section 5.             Miscellaneous.

 

a)           No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.

 

b)           Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)           Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

d)           Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase
rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares
may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment
for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from
all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to

 

    	 	14	 

     

    

 

protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)
not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be,
necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof.

 

e)           Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of
this Warrant shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the “New
York Courts”). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Warrant. If any party shall commence an action or proceeding to enforce any provisions of this Warrant, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred in the investigation, preparation and prosecution of such action or proceeding.

 

f)             Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g)           Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be

 

    	 	15	 

     

    

 

sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h)       Notices.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight
courier service, addressed to the Company, at the address set forth above Attention: Lawrence A. Kenyon, Chief Financial Officer,
facsimile number +1 (609) 228-4113, email address LawrenceKenyon@OncoBiologics.com, or such other facsimile number, email address
or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile, or sent by a
nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing
on the books of the Company, or if no such facsimile number or address appears on the books of the Company. Any notice or other
communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if
such notice or communication is delivered via facsimile at the facsimile number set forth in this Section prior to 5:30 p.m. (New
York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.

 

i)       Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

j)         Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k)         Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the

 

    	 	16	 

     

    

 

benefit of any
Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)       Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)         Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n)       Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature Page Follows)

 

    	 	17	 

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	oncobiologics, inc.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	 	18	 

     

    

 

NOTICE OF EXERCISE

 

		To:	oncobiologics, inc.

 

(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2) Payment
shall take the form of (check applicable box):

  

   ̈ in
lawful money of the United States; or

 

   ̈ [if
permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).

 

(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The Warrant Shares shall be delivered to the
following DWAC Account Number:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity: 	 

	Signature of Authorized Signatory of Investing Entity: 	 

	Name of Authorized Signatory: 	 

	Title of Authorized Signatory: 	 

	Date: 	 

 

    	 	 

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [____]
all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	 	 whose address is

 

	 	.

 

	 	 

 

Dated: ______________, _______

 

	 	Holder’s Signature:	 	 
	 	 	 	 
	 	Holder’s Address:	 	 
	 	 	 	 
	 	 	 	 

 

NOTE: The signature to this Assignment Form
must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Warrant.

 

    

     

    

 

 

Exhibit
c

 

SECURITY
AGREEMENT

 

     

     

    

 

Exhibit
d

 

IP SECURITY
AGREEMENT

 

     

     

    

 

Exhibit
e

 

JOINDER
TO NOTE AND WARRANT PURCHASE AGREEMENT, SECURITY AGREEMENT AND IP SECURITY AGREEMENT

 

The
undersigned hereby agrees to become a party in the capacity of a “Purchaser” to that certain Note and Warrant
Purchase Agreement dated as of December 22, 2016, by and among Oncobiologics,
Inc. a Delaware corporation (the “Company”) and the parties identified on the signature pages thereto
as Purchasers, and in the capacity of a “Secured Party” to that certain Security Agreement and to that certain Intellectual
Property Security Agreement, each dated as of December 22, 2016 by and among the Company and the parties identified
on the signature pages of each thereto as Secured Parties, and to be bound by the terms and conditions of such agreements in such
capacity effective as of the date thereof. The undersigned hereby makes all representations and warranties of the Purchasers contained
in the Note and Warrant Purchase Agreement to the Company as of the date hereof. The undersigned hereby authorizes this
Joinder to be attached as a counterpart signature page to each of the Note and Warrant Purchase Agreement, the Security
Agreement and the Intellectual Property Security Agreement and for Schedule I of the Note and Warrant Purchase Agreement
to be updated to include the information below with respect to such Purchaser.

 

	 	“Purchaser” and “Secured Party”	 
	 	 	 
	 	 	 
	 	 	 
	 	By: 	                 	 

 

	 	Name: 	 	 

 

	 	Title:	 	 

 

	Name	Address/Facsimile
    #	Principal
    Amount	Purchase
    Price

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]